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Tuberculosis (TB) is one of the most prevalent infectious diseases worldwide and 
causes high morbidity and mortality, despite the widespread availability of effective 
antibiotics against most strains of Mycobacterium tuberculosis, which is the 
causative agent of TB.  One of the primary reasons that hinder TB control is that 
many cases of active disease go undetected or are discovered late.  This is, in large 
part, due to the relative insensitivity and limited specificity, amongst other 
limitations, of the current TB diagnostics tests.  Moreover, M. tuberculosis 
infection can be asymptomatic and latent, or cause active disease.  Therefore, an 
ideal or effective TB diagnostic needs to distinguish between these two states.  The 
aim of this study was to develop novel diagnostic reagents for M. tuberculosis 
using phage displayed peptides and nucleic acid aptamers with a view to discerning 
latent from active TB. 
 
Using a linear (X12) and constrained (CX7C) phage display libraries, five rounds of 
selection (biopanning) were performed.  Ten phage displayed peptides that bind to 
the mycobacteria surface were selected.  These phage clones were identified using 
both random clone picking and high throughput (HTP) sequencing.  A phage clone 
displaying the CPLHARLPC peptide was identified by HTP sequencing as the most 
enriched, representing 82.49% of the selected CX7C phage population.  Further 
characterization showed that it bound better to different mycobacteria species, 
including M. tuberculosis, than the unselected phage library.  Moreover, using 







CPLHARLPC peptide was shown to bind M. tuberculosis H37Rv whole cell lysate 
and not non-mycobacteria lysates.  
 
In addition, using the systematic evolution of ligands by exponential enrichment 
(SELEX) protocol and SPR technology, 2'-Fluoro-pyrimidine-RNA aptamers were 
selected against the mycobacteria ESX-3 secreted protein, EsxG.  At least five 
aptamers were identified after five rounds of selection.  Two of these aptamers, 
GH43 and GH78, not only bound EsxG with high affinities, KD 8.04 ± 1.90 nM and 
KD 78.85 ±9.40 nM respectively, but also preferentially bound EsxG better than the 
EsxA homologue. 
 
Taken together, these findings suggest that a combination of phage display, SELEX 
and HTP sequencing can be a useful tool for the identification of specific detection 
reagents that can bind to mycobacteria and its associated targets.  These reagents 
could be exploited to develop alternative molecular probes for TB diagnostics. 
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CHAPTER 1:  INTRODUCTION AND LITERATURE REVIEW 
 
1.0   Introduction 
Tuberculosis, which is caused by M. tuberculosis, remains one of the major infectious 
diseases that lead to morbidity and death.  Despite the widespread availability of 
effective antibiotics against drug sensitive M. tuberculosis, the World Health 
Organisation (WHO) estimates that in 2011 there were between 8.3 and 9.0 million 
incidences of TB globally of which 26% were in Africa (Figure 1.1).  In the same year, 
there was an estimated 0.8 to 1.1 million deaths of HIV negative people globally that 





Figure 1. 1:  Estimated tuberculosis (TB) incidence rates, 2011 (WHO, Global 
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The difficulty in controlling the spread of TB can be attributed to several reasons.  These 
include the emergence of drug resistant M. tuberculosis strains (Senior, 2009), the 
considerable effort and expense incurred by supervising directly observed therapy 
(DOTS) and the socio-economic challenges that made continued supervision of 
treatment difficult.  However, one of the primary reasons that hinder TB control is that 
many cases of active disease go undetected or are discovered late (Storla et al., 2008, 
Reid & Shah, 2009).  This is largely due to several limitations of current TB diagnostics 
such as low sensitivity and low specificity (Sohn et al., 2009) and are reviewed in 
section 3.0 of this chapter.  An additional complication in the diagnosis of TB is that M. 
tuberculosis infection can be latent or cause active disease.  In an individual with an 
efficient cell-mediated immunity, the tuberculosis infection may be arrested permanently 
and subclinically.  This state is called the latent TB infection (LTBI) or persistent state. 
However, if the initial infection cannot be controlled or the infected person becomes 
immunocompromised, infection may progress to the extent that it becomes clinically 
detectable.  This state is called active TB (Dannenberg, 1994).  This poses a particular 
challenge because it cannot be distinguished from latent TB using most of the current 
diagnositics.  In addition to being able to distinguish latent from active TB, an ideal 
diagnostic should be affordable, sensitive, specific, user-friendly, rapid, equipment-free 




Generally, two broad approaches are used to develop diagnostic tests.  First, host 
associated markers with levels or activity that are changed in response to the pathogen, 
can be measured.  Serological antibody detection tests that measure the circulating 
antibody response to M. tuberculosis antigens are an example of this kind of diagnostic 
test.  The second approach is to detect the M. tuberculosis bacilli and/or a part of the 
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bacilli.  The main advantage of this approach is that it provides a direct evidence of 
bacterial presence.  Morevoer, this approach is more likely to differentiate between 
LTBI and active disease.  For this reason, this study adopted the second approach and 
targeted the the M. tuberculosis cell surface and its secreted protein EsxG for the 




The literature review summarizes the current knowledge on M. tuberculosis with a focus 
on the cell wall and type VII secretion system, to give context to their use as selection 
targets for this project.  Also included, is a review of the limitations and advantages of 
the current TB diagnostics.  Phage display and aptamer technology are also reviewed, 
focusing on their application in diagnostics.  Finally, the scope and the objectives of the 




2.0   Mycobacterium tuberculosis 
M.tuberculosis belongs to the Mycobacterium genus.  There are currently more than 120 
recognised species of mycobacteria (Lettieri, 2007, Tortoli, 2006).  The mycobacteria 
bacillus has variable lengths between 1.5 and 4.0 µm depending on the period of culture, 
and a diameter of 0.3-0.5 µm (Wayne and Diaz, 1986).  There are two groups of 
mycobacteria, fast growers like M. smegmatis and slow growers like M. tuberculosis.  
The fast growing species are characterised by their ability to form colonies on solid 
media in less than 7 days while the slow growing species require more than 7 days 
(Shinnick and Good, 1994).  Generally, the slower growing species are pathogenic to 
humans and animals while this is not usually the case with the faster growing 
mycobacteria species (Shinnick and Good, 1994).   
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Although M. tuberculosis is the predominant cause of human TB, other mycobacteria 
species can cause human and/or animal TB.  These species are grouped together within 
the Mycobacterium tuberculosis complex (MTBC).  The MTBC consists of closely 
related organisms namely, M. tuberculosis, M. africanum, M. bovis, M. bovis BCG, M. 
caprae, M. microti, M. pinnipedii, and M. canettii (Brosch et al., 2002, Cousins et al., 
2003, Cousins et al., 1994, Tsukamura et al., 1985).  The mycobacteria characteristic of 
interest for this study is its complex cell envelope and the associated specialised type VII 




2.1   The cell envelope of M. tuberculosis 
The cell envelope of M. tuberculosis is a complex structure with diverse components 
that can serve as potential biomarkers for suitable diagnostics.  It comprises mainly of 
two segments, the cytoplasmic inner membrane (IM) and the cell wall.  The cell wall 
segment consists of a peptidoglycan layer (PG) that is covalently attached to 
arabinogalactans (AG) (Figure 1.2).  Arabinogalactans are in turn attached to mycolic 
acids, which have long meromycolate and short α-chains and account for 30 to 40% of 
the cell envelope mass.  These form part of the mycobacterial outer membrane (MOM).  
The MOM also consist of a large variety of non covalently bound extractable lipids 
(Daffe and Draper, 1998), some of which have longer fatty acids that complement the 
shorter α-chains of the mycolic acids, while others have shorter fatty acids that 
complement the longer chains.  Distributed amongst the MOM are cell wall proteins, 
pore forming proteins, (Niederweis, 2003), phosphatidylinositol mannoside (PIMS), 
phthiocerol-containing lipids, lipomannan (LM) and lipoarabinomannan (LAM) 
(Brennan, 2003a). 





Figure 1. 2:  Schematic of the mycobacteria cell wall 
Schematic representation of the mycobacterial cell envelope adapted from (Cook et al., 
2009).  Mycolic acids which are covalently linked to the arabinogalactan (AG)–
peptidoglycan (PG) co-polymer are drawn in red and inserted in the folded conformation 
as part of the inner leaflet of the mycobacterial outer membrane (MOM).  As part of the 
MOM, a porin is represented in blue, an unidentified cell wall protein in red, while the 
extractable lipids are represented in black.  The inner membrane (IM) and the 




Indeed, diagnostics based on bacterial components are successfully used in a variety of 
infections, including Legionella (Dominguez et al., 1999), Cryptococcus (Frank et al., 
1993) and Histoplasma (Connolly et al., 2007).  Morevoer, the mycolic acids of 
mycobacteria which are species specific, have previously been investigated for TB 
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(Butler and Guthertz, 2001, Butler and Kilburn, 1988) and electrospray ionization-
tandem mass spectrometry (Song et al., 2009).  However, these tests are limited in that 
they are laboratory based tests and can only be used on cultured mycobacteria and not 




A test for a mycobacterial glycolipid, lipoarabinomannan (LAM), has recently been 
evaluated on both urine and sputum, although it is limited by the low sensitivity  range 
of 6%-50.7% although it showed a good specificity range between 87-100% (Dheda et 
al., 2010, Hamasur et al., 2001, Reither et al., 2009).  There are likely to be numerous 
other cell wall components that are shed by the bacterium and can be possibly detected 
in patients’ samples.  The primary reason that LAM has been investigated further is that, 
unlike many other M. tuberculosis glycolipids, it is antigenic and, therefore, 
straightforward to measure by enzyme-linked immunosorbent assay (ELISA).  Since 
many of the potential targets on the surface of the bacterium are glycolipids and are 
unlikely to be antigenic, the conventional use of an antibody as a detection probe will be 
limited against some of the cell wall components.  Hence, this research project explored 
alternatives to antibodies such as phage displayed peptides and nucleic acid aptamers to 




Mycobacteria like other intracellular pathogens secrete proteins to stimulate a supportive 
environment for survival and replication during infection of the host.  To achieve this, 
mycobacteria uses at least four pathways to transport proteins across its impermeable 
cell wall.  These are the SecA1 mediated general secretory pathway (Pugsley, 1993, 
Wiker and Harboe, 1992), SecA2-operated pathway (Braunstein et al., 2003), the twin-
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arginine translocation system (McDonough et al., 2008, Saint-Joanis et al., 2006) and 




2.2   The type VII secretion (T7S) system of M. tuberculosis 
In the virulent strain of M. tuberculosis the T7S system consists of five paralogous gene 
clusters namely, ESX-1 (genes Rv3866-Rv3883c), ESX-2 (Rv3884c-Rv3895c), ESX-3 
(Rv0282-Rv0292), ESX-4 (Rv3444c-Rv3450c) and ESX-5 (Rv1782-Rv1798) (Gey Van 
Pittius et al., 2001, Smith, 2003).  Of the five ESX loci, only three have been 
demonstrated to encode functional secretion systems in mycobacteria.  These are ESX-1 
which is required for secretion of virulence factors (Ganguly et al., 2008, Lewis et al., 
2003, Smith, 2003, Stanley et al., 2003), ESX-3 which is required for optimal iron 
acquisition under low iron environments (Serafini et al., 2009, Siegrist et al., 2009) and 
ESX-5 which exports Pro-Glu (PE), pro-pro-glu (PPE) and proline-glutamic 
acid_polymorphic guanine-cytosine-rich sequence (PPE_PGRS) proteins, that are 











Figure 1. 3:  The five ESX systems and their corresponding secreted WXG100 
protein.   
The Esx proteins corresponding to each T7S system gene cluster are indicated below its 
associated ESX secretion system illustration.  Several other substrates have been 
demonstrated to be secreted by the ESX secretion systems and are not depicted in this 
fugure.  Of the five ESX loci, only three (indicated by the solid arrow), ESX-1, ESX-3 
and ESX-5, have been demonstrated to encode functional secretion systems in 




One of the extensively characterised T7S secreted proteins is the ESAT-6:CFP10, also 
known and the EsxA:EsxB protein complex that is secreted by the ESX-1 secretion 
system (Smith, 2003, Stanley et al., 2003), and is required for pathogenicity of M. 
tuberculosis (Guinn et al., 2004, Hsu et al., 2003, Lewis et al., 2003, Pym et al., 2002).  
Both EsxA and EsxB proteins are part of the 23 small (EsxA-W) secreted proteins in M. 
tuberculosis that belong to the WXG100 family and are encoded by the esx gene pairs.  
This protein family is characterised by their size of approximately 100 amino acids, their 
helical structure and a helical bend that is formed by the conserved Trp-Xaa-Gly (W-X-
G) motif (Pallen, 2002).  There are 11 genomic loci in the M. tuberculosis genome that 
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by the genes coding for components of the T7S system (ESX-1-ESX-5), which is 
involved in the export of Esx proteins (Abdallah et al., 2007, Champion et al., 2006, Gey 
Van Pittius et al., 2001).  This duplication of the esx gene clusters is also present in other 
mycobacteria species including M. bovis, M. laprae, the non pathogenic mycobacteria 
strain M. smegmatis (Gey Van Pittius et al., 2001).  Interestingly, M. leprae which is 
believed to possess the minimal gene set required for pathogenesis has only retained the 
genes corresponding to the esx cluster 1 and cluster 3 (Cole, 2001, Gey Van Pittius et al., 
2001).  This suggests that these two esx gene clusters are essential for either 
mycobacteria virulence or growth.  Indeed, the ESX-3 system is the only ESX system 
that is essential for growth in M. tuberculosis (Sassetti et al., 2003), while ESX-1 is 
essential for virulence of mycobacteria.  Of relevance to this thesis is the ESX-3 




2.3   The mycobacteria ESX-3 secterion system 
The Esx-3 secretion system has been implicated in mycobacteria growth under low iron 
conditions (Serafini et al., 2009, Siegrist et al., 2009).  Iron, is an essential nutrient for 
most microorganisms.  At least 40 enzymes encoded by the M. tuberculosis genome 
require iron as a cofactor (Cole et al., 1998).  Iron acquisition is a challenge for 
intracellular pathogens as it is not freely available in the host, but instead is tightly 
bound to iron-binding host proteins (Weinberg, 1999).  For this reason, successful 
intracellular pathogens have evolved complex ways to overcome the iron limited 
environment experienced in the host during infection.  Mycobacteria are no exception, 
as, there is now evidence indicating that M. tuberculosis does in fact encounter low iron 
conditions during infection of macrophages (Gold et al., 2001).      
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One of the ways that mycobacteria has evolved to acquire iron is by the use of small-
molecule compounds, called siderophores, for high affinity chelating of ferric iron 
(Miethke and Marahiel, 2007).  The siderophores are generally secreted by the organism 
to compete for the available iron in their environment (De Voss et al., 1999).  The genus 
of mycobacteria has two kinds of siderophores, mycobactin and exochelin (Gobin and 




While non pathogenic mycobacteria such as M. smegmatis, produce both mycobactin 
which are molecules distinguished mainly by the presence of a phenyloxazolidine ring 
(Harrison et al., 2006), and exochelin which is a peptidic siderophore (Ratledge and 
Ewing, 1996), the pathogenic M. tuberculosis produces two classes of mycobactin, 
namely carboxymycobactin which is a more polar form and is secreted by the bacillus 
and mycobactin that is less polar and is cell bound (Ratledge, 2009).  The synthesis of 
the siderophoresis is highly regulated, occurs exclusively under low iron conditions 
(Rodriguez et al., 2002), and is essential for growth in low iron medium.  DeVoss and 
colleagues (2000) demonstrated this by showing that a mutant strain (mbtB) of M. 
tuberculosis which is defective in the synthesis of mycobactin is unable to replicate in 




Iron homeostasis in M. tuberculosis is mainly maintained by the iron-dependent 
regulator (IdeR) protein.  In the presence of iron, IdeR binds to the promoters and 
represses the transcription of mbt genes which are essential for siderophore synthesis 
(Gold et al., 2001).  In addition, IdeR represses the transcription of the ESX-3 gene 
cluster in both M. tuberculosis (Rodriguez et al., 2002) and M. smegmatis (Maciag et al., 
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2009), while low iron conditions induce the transcription of the ESX-3 cluster in M. 




One of the known substrates of ESX-3 is the EsxG:EsxH heterodimer (Lightbody et al., 
2004, Siegrist et al., 2009).  A recent study by Siegriest and colleagues (2009) 
demonstrated that a M. smegmatis mutant which lacks ESX-3 (∆ESX-3) is unable to be 
rescued by the exogenous addition of purified siderophore, mycobactin, indicating that 
the mutant is unable to use iron-bound mycobactin.  Serafini and colleagues (2009) 
reported similar findings using a M. tuberculosis ESX-3 conditional mutant.  Serafini 
and colleagues (2009) further hypothesised that ESX-3 is responsible for the secretion of 
some unknown factor(s) which is required for the optimal uptake of iron and zinc.  Since 
EsxG and EsxH are known to be secreted by the ESX-3 system, it raises the question if 
one or both of these proteins are possibly the unknown factor secreted by this secretion 




Taken together, I reasoned that since EsxG and EsxH are secreted by the ESX-3 system 
which in turn is induced under low iron conditions both of these two proteins are likely 
to be present in an infected host and can be investigated as a potential tuberculosis 
biomarker, if appropriate detection were available.  If suitable reagents that can detect 
either EsxG or EsxH were developed, they would also be useful tools to study the role of 
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3.0   Current TB diagnostics 
 
The various available TB diagnostic tests fall in two major groups, those that detect the 
pathogen and/or itsassociated biomarkers and those that measure host associated 
biomarkers in response to the pathogen infection.  Both groups of tests have advantages 
when applied in an appropriate environment but also posess inherent limitations. 
However, to date we do not have but urgently need, a TB diagnostic with high 
specificity and sensitivity and also offers the ease of use at point of care fascilities in 




3.1   Direct detection of MTBC or its associated components in clinical samples 
 
3.1.1  Sputum smear microscopy 
The most widespread test for diagnosing TB is the sputum smear microscopy test.  This 
test detects mycobacteria by staining and identification of acid fast bacteria (AFB) under 
a microscope.  There is a conventional smear microscopy test which uses a light 
microscope to detect AFB on the sputum sample.  Its sensitivity is up to 70–80% in 
some settings (Steingart et al., 2007c) but it cannot detect paucibacillary disease.  The 
sensitivity of smear microscopy is iimproved by the use of a fluorescence microscope 
that uses an acid-fast fluorochrome dye to stain the mycobacteria for visualising under 
the microscope (Kivihya-Ndugga et al., 2003, Bell and Brown, 1962, Githui et al., 
1993).  While this test only requires one piece of equipment which is a microscope, it 
still needs trained personnel to be conducted effectively.  Both of these requirements 
necessary for smear microscopy might to be a limitation for their adoption in resource 
limited settings.  Furthermore, the test sensitivity is significantly lower in areas with 
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high HIV prevalence due to a low bacterial burden in sputum of HIV positive patients 




3.1.2  Solid Culture 
Culture based tests are based on detection of mycobacteria growth on specialised culture 
medium.  The culture based methods are still the gold standard in TB diagnostics.  They 
can be performed in liquid culture as described in 3.1.3 or in solid culture like the 
Lowenstein-Jensen medium.  The main advantage of culture tests is that they offer a 
higher sensitivity than smear microscopy as they can detect as low as 10 bacilli per 
milliliter of sputum when compared to the minimum range of detection by smear 
microscopy of 5000 - 10000 bacilli per millilitre of sputum (American Thoracic Society. 
Committee on Revision of Diagnostic, 2000).  However, the major lmitatation of this 
test is that it can take up to eight weeks to get the result as it is dependent on bacterial 




3.1.3  Automated Liquid Culture 
Liquid culture methods offer a quicker turnaround time from sample collection to 
diagnosis when compared to solid culture medium, without a compromise on sensitivity.  
For example, the previous radiometric system Bactec TB 460 (Becton-Dickinson, USA) 
required on average 13 days to give a positive result for TB (Abe et al., 1992).  
However, it had its limitations.  In addition to complexity of performing this test, the 
Bactec TB 460 system used radioisotopic reagents which required specialised disposal 
methods resulting in additional costs associated with performing the test (Palacios et al., 
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1999).  However, there are now less complex, automated systems based on liquid culture 
that do not require the use of radioisotopic reagent.  These include the BACTEC 9000 
MB system which has an average time of 10 days to mycobacteria detection (Pfyffer et 
al., 1997a, Zanetti et al., 1997), the Difco ESP Culture System II which averages 13.1 
days to detection of MTBC (Woods et al., 1997) and the MB/BacT system (Palacios et 
al., 1999) which takes an average of 13.2 days to mycobacteria detection (Nogales et al., 
1999) and and can also be used for antibiotic drug susceptibility (Diaz-Infantes et al., 
2000).  Furthuremore, there are now culture tests like the the BBL Mycobacteria Growth 
Indicator Tube (MGIT) that do not require instrumentation but can be inspected visually 
for mycobacteria detection (Pfyffer et al., 1997b).  The test requires on average 9.9 days 
to detect mycobacteria (Pfyffer et al., 1997b).  While great improvements had been 
achieved in improving the time to detection using liquid cultures, these test fall short of 
being used at point of care and require trained personeel to be performed correctly.  This 




3.1.4  Nucleic acid amplification test (NAAT) 
Nucleic acid amplification tests (NAAT) are based on amplification of nucleic acids 
from MTBC using various nucleic acid amplification techniques.  There are three main 
NAAT, the Amplified Mycobacterium tuberculosis Direct (MTD) Test™ (Gen-Probe®, 
San Diego, CA), the Amplicor® Mycobacterium tuberculosis (Amplicor MTB) Test 
(Roche® Diagnostic Systems, Branchburg, NJ) and the GeneXpert MTB/RIF assay 
(Cepheid, Sunnyvale, CA).  The MTB and the Amplicor MTB test have been shown to 
have a detection sensitivity between 83% and 100% and a specificity between 97% and 
100% when compared to culture (Moore et al., 2005).  The most recent of these tests, the 
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GeneXpert, has been shown to have a turnaround time of less than 2 hours and a 
detection limit of approximately 100 organisms (van Zyl-Smit et al., 2011).  Thefast 
turnaround time to MTBC detection and the high sensitivity and specificity of these tests 
offers a much needed improvement in TB diagnostics.  However, the cost of the 
equipment, the consumables and the training of personnel required by these tests limits 




3.1.5  Loop mediated isothermal amplification (LAMP) test 
The LAMP test is based on the amplification of a target gene in mycobacteria without 
the use of a thermocycler.  The LAMP test is performed in a single tube with all the 
reagents, and the reaction occurs in 60 min, under isothermal conditions between 60ºC -
65ºC.  The results of the test can be acquired without the use of instrumentation by 
adding SYBR Green I to the reaction.  The test has been successfully used to detect M. 
tuberculosis by targeting the gyrB gene (Iwamoto et al., 2003) and the16S rRNA 
(Pandey et al., 2008).  At the reaction time of 60min, the LAMP test using primers 
targeting the gyrB gene showed similar sensitivity to the Amplicor MTB test for the 
detection of MTBC, with a detection limit of 5 to 50 copies of purified DNA (Iwamoto 
et al., 2003).  The LAMP test offers a simpler alternative to the conventional NAAT, 




3.1.6  Lipoarabinomannan (LAM) antigen detection test 
The test detecting the mycobacterial glycolipid, LAM, has demonstrated that detection 
of TB associated components can be exploited in the development of TB diagnostics.  A 
metanalysis review by Flores and colleagues (2011) showed that this test has a 
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sensitivity of 87% in sputum and 53% in urine (Flores et al., 2011).  They further 
showed that the sensitivity of the test is higher (47%) in HIV-infected individuals when 
compared to HIV-uninfected (14%) individuals.  While the LAM test offers a good 
proof-of-principle that an antigen detecting test can be performed on easily obtainable 
clinical samples like urine, the low sensitivity of the test remains a limitation in its use 




3.1.7  Phage amplification test 
Phage amplification tests use bacteriophages to infect live M. tuberculosis and detect the 
bacilli by subsequently amplifying the phage (Wilson et al., 1997) or detecting the light 
that is emitted by the phages with a luciferase reporter after they have infected the live 
bacilli (Jacobs Jr et al., 1993).  A meta-analysis study by Pai and colleagues (2005) 
showed that of the two studies included in their meta-analysis which performed phage 
assays directly on sputum; one study reported a sensitivity of 100% and a specificity of 
99% (Albert et al., 2004), while the other reported a sensitivity of 86% and specificity of 
73% (Butt et al., 2004, Pai et al., 2005).  While the sensitivity and specificity of this test 
is higher than that of smear microscopy, its limitation is that it requires equipment 
similar to that of culture based test and can only be performed in a laboratory 




3.2   Indirect detection of MTBC infection by measuring host associated 
biomarkers 
The major limitation shared by this group of diagnostic test is the inability to 
differentiate between latent and active TB infection.  Nonetheless, in settings where TB 
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is not prevalent or an alternative diagnostic test is either not available or effective, some 




3.2.1  Tuberculin skin test (TST) 
This test measures the patients’ immune response to M. tuberculosis purified protein 
derivative (PPD).  While the test has been successfully used for diagnosis of latent TB, it 
has limitations which include subjectivity in the administration and reading of the test 
results.  Furthuremore, BCG vaccination increases the probability of a positive TST 
result in the absence of latent infection (Wang et al., 2002).  The cross reactivity of this 
test with BCG vaccination wich is still used in countries with a high burden of TB 
disease, and the inability of the test to distinguish latent from active TB, limits its 




3.2.2  Serological antibody detection test 
The serological antibody tests are based on the detection of antibodies against M. 
tuberculosis in clinical samples.  While serological tests are successfully used against 
other pathogens, the sensitivity and specificity results from these tests in TB diagnsostic 
are very variable and inconsistent (Steingart et al., 2007b, Steingart et al., 2007a).  This 
is the primary reason that the WHO in July 2011 issued a warning that serological blood 




3.2.3  Adenoside deaminase (ADA) 
This tests measures the levels of ADA, a purine degrading enzyme implicated in 
mononuclear phagocyte maturation (Fischer et al., 1976, Carson and Seegmiller, 1976), 
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in pleural fluid (Greco et al., 2003).  This test sensitivity for pleural fluid ADA of ≥50 
U·L−1 was shown to be 95% and specificity 89% when compared to thoracoscopy, 
which is the most sensitive test for diagnosis of TB pleurisy (Diacon et al., 2003).  This 
test offers an alternative to the diagnosis of TB pleurisy in settings where thoracoscopy 




3.2.4  T-cell-based interferon-y release assays (IGRA’s) 
The gamma interferon (IFN-γ) release assays (IGRA) are based on the measurement of 
the IFN-γ release by foreign epitope-stimulated T cells (Tsiouris et al., 2006).  An IGRA 
test using ESAT-6 and CFP-10 antigens was demonstrated to have a specificity of 
98.1% and the sensitivity of 89.0% (Mori et al., 2004).  This type of test is commercially 
available as QuantiFERON-TB Gold In-Tube (Cellestis Inc, Carnegie, Australia).  
Another commercially available IGRA is the T-SPOT.TB (Oxford Immunotec Ltd, 
Abingdon, UK), which measures the total number effector T cells expressing IFN-γ.  
The main advantage of the IGRAs is that they simultaneously respond to multiple 
targets, which allows for continues improvement of the specificity and sensitivity if 
multiple specific targets are identified and tested.  The main limitation is that to perform 
the test, trained personnel and specialised equipment is required which limits it 




Considering the various inherent limitations in the current TB diagnostics, there is an 
urgent need to develop a test that can be used at point-of-care (POC).  The advantage of 
a test that detects the pathogen or a pathogen associated marker is that it can distinguish 
between latent and active disease.  However, the challenge in selecting a pathogen 
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biomarker is that they are likely to be present in low concentrations in clinical samples.  
To date, antibody based tests have performed poorly, showing mainly low specificity.  
For this reason this study investigated the use of nucleic acid aptamers, as well as phage 




4.0   Aptamers in diagnostics 
Traditionally, antibodies are used as detection probes in diagnostic applications.  In the 
past, one of the major limitations in the use of antibodies in diagnostic was attaining 
adequate production scales to meet market needs.  However, improvements in the 
antibody production processes today have enabled monoclonal antibodies to be 
produced indefinitely by continuous culturing of a single selected clone resulting in 
culture processes that can produce up to 5 g/l of antibody concentration (Birch et al., 
2008, Winder and Rob, 2005).  Indeed, this advance in antibody production has enabled 
continuous use of antibodies in various applications including diagnostics.  Nonetheless, 
there are still limitations in the use of antibodies as diagnostic probes (Jayasena, 1999) 
These include the batch to batch variation of antibodies which require an immunoassay 
to be performed and re-optimised for each produced batch.  Also, antibody-target 
binding properties cannot be changed on demand.  In addition, their sensitivity to 
temperature which results is an irreversible denaturing, limits their application in 
diagnostics as the final environment cannot always be regulated.  Antibodies also bind to 
a restricted number of macromolecules which are "antigenic".  To address some of these 





 Chapter One: Introduction 
 
20 
Aptamers are artificial nucleic acid or peptide ligands which are selected using an in 
vitro process and bind to a specific target molecule with high specificity and affinity.  
Their ability to recognize and bind their targets is similar to that of antibodies (Tasset et 
al., 1997, Xu and Ellington, 1996).  They can be potent inhibitors of protein function 
(Kumar et al., 1997), which also makes them applicable as ideal candidates in drug 
development as well as pathway elucidation in scientific research.  For example, there is 
already an FDA-approved RNA aptamer, Macugen, which is an inhibitor of vascular 
endothelial growth factor (VEGF) and is used for the treatment of age-related macular 
degeneration (AMD) (Lee et al., 2005).  In addition, aptamers also offer the following 
advantages as alternatives to antibodies: 
• The in vitro selection of aptamers simplifies their identification when compared 
to the in vivo selection of antibodies 
• Unlike antibody selection, which is limited to in vivo conditions, aptamer 
selection conditions can be varied to support their intended use in the final 
diagnostic assay.   
• Antibodies are difficult to generate against non-antigenic or toxic molecules, 
but the in vitro selection process of aptamers enables their selection against 
such targets. 
• The chemical synthesis of aptamers versus the common cell culture methods 
used in the production of antibodies allows for minimal batch to batch 
variations. 
• In addition, chemical synthesis of aptamers also allows for the attachment of 
functional groups which enable simple derivatisation of aptamers with other 
reporter molecules such as biotin and fluorescein for ease of detection or read 
out in diagnostic applications. 
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• Finally, the temperature stability and reversible denaturing ability of aptamers 
allows for long term storage and ease of transportation at ambient temperature 
which is of benefit especially in POC diagnostic assays which in the case of TB 





4.1   Nucleic acid aptamers in diagnostics 
Nucleic acid aptamers have been developed for diagnostics purposes.  These include a 
thrombin-binding DNA aptamer (Tombelli et al., 2007) which has been investigated in 
various assays (Baldrich et al., 2004, Cai et al., 2002, Gronewold et al., 2005, Radi et al., 
2006, Zhang et al., 2006) for the diagnosis of diseases associated with coagulation 
abnormalities.  Another aptamer with diagnostic potential is the RNA aptamer that bind 
to S-adenosylhomocystein (SAH), which has potential for use in the diagnosis of 
cardiovascular disease (Gebhardt et al., 2000).  At least three nucleic acid aptamers have 
been developed that can detect whole cell bacterial pathogens.  These include aptamers 
that can detect Campylobacter jejuni (Tombelli et al., 2007), which is the most common 
cause of food borne infections (Altekruse et al., 1999), DNA aptamers that detect 
Francisella tularensis (Tombelli et al., 2007) which causes tularemia and DNA 
aptamers that bind M. tuberculosis (Chen et al., 2007).  One DNA aptamer (NK2) 
selected against M. tuberculosis H37Rv has been shown to prolong the survival rates of 
mice challenged with intravenous therapy H37Rv and is being further evaluated for its 
therapeutic potential (Chen et al., 2012).  This success in aptamer selection has led to 
continuous investigation of aptamers as detection probes in diagnostics. 
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The use of aptamers in point of care diagnostics has been explored in various platforms. 
Aptamers have been successfully demonstrated to be adaptable to POC detection 
methods previously developed for antibodies.  These include the use of aptamers in 
different biosensor platforms (Navani and Li, 2006) like the quartz crystal protein 
biosensor (Liss et al., 2002) and the rapid plasmon resonance biosensor (Proske et al., 
2005).  However, aptamer-based biosensors are currently not user-friendly for use at 
point of care.  The ideal POC test for TB in resource limited settings will need a 
colorimetric read out system, where the results can be interpreted with the naked eye.  
Two platforms with a colorimetric readout have been successfully explored using 
aptamers.  The first one uses gold nanoparticles functionalized with DNA aptamers to 
construct sensors with colorimetric read out in response to various analytes such as 
adenoside, cocaine and potassium ions (Liu and Lu, 2006).  In the second platform, Lui 
and colleagues (2006) further demonstrated a DNA aptamer based cocaine-sensing 
lateral flow device (Liu et al., 2006).  The lateral flow was used to detect varying 
concentrations of cocaine in a buffer solution as well as cocaine in undiluted human 





Nucleic acid aptamers are selected against a particular target by an invitro selection 
process called the systematic evolution of ligands by exponentialenrichment (SELEX) 
(Ellington and Szostak, 1990, Tuerk and Gold, 1990).  SELEX is an in vitro selection 
process consisting of sequential steps of selection and amplification to reduce a library 
of nucleic acids with randomised sequences to a minimised subset of one or more 
sequences that bind tightly to the target of choice (Que-Gewirth and Sullenger, 2007). 
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The first step in the SELEX process is the design and chemical synthesis of the random 
nucleic acid library.  There are three things to consider during the design of the library, 
namely the length of the random region, type of randomization and the chemistry of the 
nucleic acid pool (Marshall and Ellington, 2000).  Usually 1014 unique sequences are 
used for the initial round of selection (Gold et al., 1995).  The second step in the SELEX 
process is the selection of ligand sequences that bind to the target.  This is achieved by 
the incubation of the library with the target under appropriate temperature and buffer 
conditions (Gopinath, 2007).  Different ratios of nucleic acid to target can be evaluated 
according to the level of stringency required for the experiment.  However, the common 
practice is to start with a low ratio of nucleic acid to target, to validate whether all 
nucleic acid molecules bind the target (Marshall and Ellington, 2000).  The third step of 
SELEX involves the use of various partitioning methods to separate the sequences that 
bind to the target from non-binding sequences.  Advantages and limitations of the 
various partitioning methods, which include the use of nitrocellulose membrane 
filtration, affinity surfaces, column matrices, centrifugation, surface plasmon resonance 





Successful use of the SPR based SELEX, which was adopted for this study, has been 
previously reported.  These include RNA aptamers selected against the surface envelope 
glycoprotein (gp120) of the HIV-1 Ba-LR5 strain (Khati et al., 2003) and those selected 
against the human influenza virus hemagglutinin (Misono and Kumar, 2005).  The SPR 
SELEX is based on an optical method that measures the refractive index on a sensor 
surface and is reviewed by (Van Der Merwe, 2000).  In brief, the Biacore system is the 
most common SPR instrument used and has a sensor surface that forms the floor of a 20-
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60 nl flow cell, with a continuous flow of running buffer.  Typically, one molecule (the 
ligand) is immobilized onto the sensor surface and its binding partner (the analyte) is 
injected in a sample buffer through the flow cell, to monitor their interaction.  Real time 
measurements are acquired as the analyte binds to the ligand.  This results in an increase 
in the refractive index and is plotted as the response units (RUs) (Van Der Merwe, 




The final step of the SELEX process involves the amplification of bound aptamers to be 
used as input library in the following round of SELEX.  For nucleic acid aptamers the 
amplification of the bound sequences is achieved by PCR and in the case of RNA 
aptamers, this is followed by in vitro transcription to convert the DNA into RNA.  
Traditional SELEX usually consists of 8-12 rounds of selection (Bowser, 2005).  At the 
end of SELEX, monoclonal binding sequences are selected from the final population 
and validated for binding to their target. 
 









4.2   Phage display in diagnostics 
There are several technologies available for the selection of peptide reagents.  These 
include phage display technology, the two-hybrid approach, ribosome display and the 
mRNA display (James, 2001).  This study adopted the phage display technology 
approach for the selection of peptides that bind to M. tuberculosis.  Phage display has 
previously been used to identify peptides with diagnostic potential.  Anandakumar and 
colleagues used a phage library that displayed 12-mer random peptides to identify 
candidate peptides for the diagnosis of opportunistic infections caused by Candida 
albicans (Anandakumar et al., 2011).  Larbanoix and colleagues (2008) used a phage 
library that displayed a 7-mer cyclic peptide on the pIII protein to isolate peptide that 









Elution of bound RNA
RNA binding to target
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Stratmann and colleagues (2002) selected 12-mer peptides using random phage display 
against M. paratuberculosis with a diagnostic potential for routine screening in bulk 




This technology was first introduced by G. Smith in 1985 (Smith, 1985).  It enables the 
display of a large number (up to 1010) of diverse peptides, proteins and antibodies on the 
surface of the filamentous phage (Azzazy and Highsmith, 2002).  The most commonly 
used phage is the M13 filamentous phage (Figure 1.5), which infects E. coli as its 
natural host (Mullen et al., 2006).  M13 is rod shaped with a circular genome of 6000-
8000 bases which is enclosed by an envelope that is made of five different proteins 
(Kehoe and Kay, 2005, Smith and Petrenko, 1997).  The phage is covered by several 
copies of the pVIII protein, while one end contains five copies of each minor proteins 
pIII and pVI.  There are 3-5 copies of the minor proteins pVIII and pXI on the other end 
of the phage.  While foreign peptides have been displayed on the N-terminus of all 
phage coat proteins (Jespers et al., 1995, Smith and Petrenko, 1997), the most commonly 
used are the pIII and the pVIII. While protein and antibody phage display libraries are in 
use, libraries that display random peptides are the most common.  Randomised 
oligonucleotides of a certain length are cloned as a fusion protein to one of phage coat 
proteins, which results in their expression as a peptide-capsid fusion proteins (Azzazy 
and Highsmith, 2002).  The phage displayed peptides can vary between 6 and 43 amino 
acids in length (Burritt et al., 1995, McConnell et al., 1996).  Furthermore, structurally 
constrained peptides have been successfully displayed and screened for target binding 
and are advantageous in selecting high affinity peptides (McLafferty et al., 1993).  




Figure 1. 5:  Schematic view of the M13 filamentous phage particle displaying a 




Target binding phage clones are selected in an invitro process called biopanning.  
Biopanning involves several steps as illustrated in figure 1.6.  In brief, the library is 
allowed to interact with the target.  This is followed by several washes to remove 
unbound phage.  Specifically bound phage will then be eluted from the ligand.  This can 
be accomplished by using a solution of a known ligand for the target to compete with the 
bound phage or adding bacterial host (Smith and Petrenko, 1997).  In a case where there 
is no known ligand for the target, a general low pH Glycine-HCl buffer can be used for 
non specific disruption of the binding interaction.  The eluted phage is amplified by 
infection of E.coli bacteria (Smith and Petrenko, 1997).  Usually three to five rounds of 
biopanning are necessary to select for a specific pool of phage.  However, biopanning 
rounds should continue until a binding assay of the enriched pool indicates that the 
selected population is enriched (Kehoe and Kay, 2005, Menendez and Scott, 2005).  The 



















5.0   Aim and objectives 
 
The aim of this thesis was to develop phage displayed peptides and nucleic acid 
aptamers, respectively, for detection of M. tuberculosis.  These reagents were developed 




Thus, the objectives of this study were: 
• To isolate phage-displayed peptides that can detect M. tuberculosis bacilli 
• To demonstrate that the isolated peptide reagents could bind their M. tuberculosis 
targets in different forms, namely, intact bacilli and lysed bacilli.  
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6.0   Structure of the thesis 
 
In Chapter 2, the biopanning experiments against M. tuberculosis from two phage 
display libraries are described.  This chapter describes the different binding properties of 
phage pools enriched from three different biopanning experiments, highlighting the 
importance of optimizing biopanning for each target.  Subsequently, the phage pools 
resulting from the final biopanning protocolexperiment were assessed for enrichment 
using high-throughput sequencing (HTS) and validated by characterising their ability to 
bind the targeted M. tuberculosis.  High-throughput sequencing (HTS) in addition to the 
traditional random clone picking method, were used to identify the highly enriched 




In Chapter 3, the phage clones identified using both methods are assessed for enrichment 
and ability to bind mycobacteria.  The highly enriched phage clone as identified by HTS 
was characterised for binding to its target using different species of mycobacteria.  The 
displayed peptide was further synthesized.  Furthurmore, the binding specificity and the 




Chapter 4 describes the isolation of RNA aptamers with nanomolar affinities against the 




Finally, Chapter 5 provides a general discussion and conclusion to the thesis. 
 
















DEVELOPMENT OF PEPTIDE APTAMERS AGAINST SURFACE EXPOSED 
TARGETS ON M. TUBERCULOSIS, USING PHAGE DISPLAY TECHNOLOGY 





















Bacterial cell wall components have been previously used as infection biomarkers 
detectable by antibodies.  However, the surface of the Mycobacterium tuberculosis, the 
causative agent of tuberculosis, is mainly composed of glycolipids which are unlikely to 
be antigenic.  This makes the probing of biomarkers on the surface of M. tuberculosis 
cell wall limited, using antibodies.  Phage display is an approach that can find peptides 
that bind their targets with high affinity using the selection process called biopanning. 
The success of the biopanning experiment is dependent on various steps during the 
protocol.  These include the immobilization of the target, the stringency in the removal 
of unbound phages through multiple washes and the strategy for elution of bound phages 
from the target.  In this chapter, I investigated three biopanning protocols with varied 
strategies for immobilization of the target, stringency of the washing steps as well as 
elution methods.  I demonstrated that the immobilization of M. tuberculosis intact bacilli 
on a surface treated for binding both hydrophilic and hydrophobic molecules performed 
better than both the untreated surface and in-solution biopanning against the M. 
tuberculosis bacilli.  Furthermore, I found that the elution strategy using both low pH 
and sonication resulted in an enriched pool with higher binding signal to the targeted M. 
tuberculosis bacilli when compared to the conventional low pH elution strategy without 
sonication.  I further confirmed the enrichment of the selection using high-throughput 
Illumina sequencing, showing the reduction in the diversity of the selected pools 
throughout the selection protocol.  Taken together, this data supports the use of phage 
display technology to enrich for a population of peptides that bind mycobacteria, which 
can be further investigated as detection reagents for potential TB biomarkers. 
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1.0   Introduction 
 
Pathogen-associated biomarkers, have advantages over current immunological 
biomarkers as they identify the presence of an organism that is independent of the state 
of the disease, such as active and latent TB.  Thus far, the only available pathogen-
associated tests that are used - mainly on sputum samples are smear microscopy, culture 
(Levy et al., 1989), and nucleic acid amplification tests (Davis et al., 2011, Ling et al., 
2008).  In the case of extrapulmonary TB, or in pediatric and immunocompromised 
patients, where individuals would have difficulty producing a sputum sample or the 
bacilliary burden is low, tests that probe for biomarkers that can be detected in samples 
other than sputum are critical.  Currently, these include assays that detects LAM (Chan 
et al., 2000, Sada et al., 1992) in urine, the volatile organic compounds breath test (Fend 
et al., 2006, Phillips et al., 2007), and whole blood culture (Ravn et al., 2005, Wallis et 
al., 2001).  However, all these tests have varying limitations which include low 
sensitivity, low specificity or poor cost-effectiveness (reviewed in detail in chapter 1).  





I hypothesised that numerous cell wall associated components are shed by the 
mycobacterium during infection.  These might possibly be detected in patient samples 
such as sputum, serum and urine, if suitable detection reagents were available.  
However, it is well known that the surface of M. tuberculosis is mainly composed of 
glycolipids (Lopez-Marin, 2012) which are possibly non-antigenic.  Antibodies, which 
are the conventional reagents used for biomarker probing or pull-down assays, are 
limited, because by definition they can only identify antigenic components.  This is 
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possibly one of the reasons these potential non-antigenic biomarkers, have not yet been 
identified.  As a result, we currently do not have reagents to probe for these potential 
biomarkers in patients samples.  Thus, we employed phage display technology to 
identify peptides that can potentially bind to both antigenic and non-antigenic surface 




Panning of phage display libraries has successfully identified peptides that bind intact 
bacteria (Stratmann et al., 2002) and viruses (Chen et al., 1996).  The technology 
involves the display of a random peptide sequence appended to a recombinant viral 
protein on the surface of a bacteriophage (Adda et al., 2002).  The typical selection as 
previously detailed in chapter 1, involves exposure of the unselected library to the target, 
and removal of unbound phages.  The bound phages are then eluted and amplified by 




The biopanning protocol can be optimized for every single target.  There are invariably 
three main parts which can be varied.  First, the immobilization strategies, that can either 
be surface panning or solution phase panning.  Surface panning protocols are the most 
common, mainly because of their simplicity.  Traditionally, the target is directly coated 
onto the plastic surface.  One of the limitations of this protocol is the inaccessibility of 
the ligand binding site as a result of steric blocking and/or partial denaturing of the 
target along the surface (Biolabs, 2012).  Moreover, since targets have variable surface 
properties, it might be necessary to experiment with differently treated surfaces to find 
the best surface for immobilising the specific target.  Alternatively, the solution phase 
panning can be adopted, where the target is allowed to interact with the phage in 
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solution.  This can be followed by affinity capture of the phage-target complexes to 
recover the bound phage (Cwirla et al., 1990) or by simply centrifugation of the phage-
target complex (Stratmann et al., 2002).  While this protocol falls short of the technical 
simplicity of surface immobilisation, it offers two main advantages.  First, during 
solution panning, all the potential ligand binding sites on the target are accessible to the 
phage.  Second, using this protocol minimizes the potential denaturing of the target that 




The second variable part of the biopanning protocol is the washing steps to remove 
target unrelated binders.  Stringency in the washing step is usually influenced by 
increasing the amount of detergent in the washing buffer and/or raising the number of 
washing steps in the successive rounds, allowing for the removal of any target unrelated 





The last variable part of the biopanning protocol is the elution strategy used to recover 
target binding peptides.  In the case where a ligand of the target is known, competition 
elution is an option.  However, non-specificelution using low pH buffers is commonly 
used (Koivunen et al., 1994, Koolpe et al., 2002, Lowman et al., 1991, Verhaert et al., 
2002).  Different non-specificelution protocols are reviewed by Lunder and colleagues 
(2008), and they demonstrated that the addition of sonication to low pH elution results in 
a single step isolation of high affinity peptides. 
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Traditionally, at the end of biopanning, random phage clones are selected and evaluated 
for binding to the intended target.  While this method can identify enriched clones, it is 
not able to evaluate the enrichment levels of each individual clone at the end of 
selection, nor can it assess the success of the biopanning experiment by providing the 
global trend of enrichment.  However, HTP sequencing has made possible the 
sequencing of millions of inserts allowing for a higher resolution of the selected pool of 
the displayed peptides (Dias-Neto et al., 2009, 't Hoen et al., 2011).  The reduction in the 
sequence diversity throughout the selection rounds of biopanning together with the 
analysis of the enriched peptides at the end of the selection can be used to evaluate the 




This chapter describes the three biopanning protocols evaluated for the enrichment of 
phage displayed peptides that bind to intact M. tuberculosis (∆leu/∆pan).  To evaluate 
the three panning protocols, we employed a library that displays random 7-mer peptides 
(CX7C) at the tip of the pIII minor coat protein of the M13 phage.  The displayed 
peptide is flanked by two cysteine residues, which are oxidized during phage assembly 
to a disulfide bond, resulting in a loop constrained peptide.  Three rounds of panning 
against the targeted M. tuberculosis (∆leu/∆pan) were performed using all three 
protocols and the eluates from the final round of panning were evaluated in a binding 
assay against the target.  Subsequently, biopanning protocol 3, which showed the best 
enrichment and specificity to the target after three rounds of biopanning was used to 
select for M. tuberculosis binding peptides using an additional phage library that 
displays random 12-mer peptides (X12).  Finally, HTP sequencing together with ELISA, 
which determined binding, were used to demonstrate the success of the selected 
biopanning protocol. 
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2.0   Materials and methods 
 
2.1   Bacterial strains and growth conditions 
The bacterial strains used in this study were M. tuberculosis H37Rv, M. tuberculosis 
∆leucineD and ∆panthothenateCD double auxotroph (∆leu/∆pan), M. smegmatis 
mc21551, M. bovis (BCG) and the E. coli ER2738 strain for phage amplification. 
Mycobacteria cultures were grown on Middlebrook 7H9 media (Sigma, St. Louis, MO) 
supplemented with the Middlebrook oleic albumin dextrose catalase (OADC) (bovine 
albumin fraction V 5 g/l, dextrose 2 g/l, catalase 0.004 g/l, oleic acid 0.05 g/l, sodium 
chloride 0.85 g/l) (Sigma, St. Louis, MO), 0.2% glycerol and 0.05% Tween-80.  M. 
tuberculosis (∆leu/∆pan) media was further supplemented with both leucine (50 µg/ml) 
and pantothenate (24 µg/ml) (Sampson et al., 2004).  Mycobacteria cultures were grown 
at 37ºC with agitation.  In experiments involving preserving the mycobacteria capsular 
layer, all mycobacteria cultures were grown in the absence of tween and agitation.  For 
further use, all mycobacteria were centrifuged at 8000 rpm and resuspended in carbonate 
buffer (35 mM NaHCO3, 15 mM Na2CO3 [pH 9.8]).  
The E. coli ER2738 strain was grown in Luria-Bertani (LB) medium with tetracycline 
(20 µg/ml final concentration) for amplification and to titer phage.  For the plating of the 
phage isopropyl β-D-thiogalactopyranoside (IPTG; 1mM final concentration) and 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal; 60mM final concentration) 
were added to LB agar plates before plating.  All bacterial cultures were grown at 37°C 
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2.2   Immobilization of the target mycobacteria for solid phase panning 
Mycobacteria suspensions were resuspended in carbonate buffer (35 mM NaHCO3, 15 
mM Na2CO3 [pH 9.8]) and adjusted to an optical density of 1.0 at 660 nm, 
corresponding to approximately 108 bacteria per ml (Stratmann et al., 2002).  
Polystyrene petri dish wells (Sigma Aldrich, MO, USA), used for biopanning 1 or 
MaxiSorp™ surface microtiter plate wells (Nunc, Roskilde, Denmark) used for 
biopanning 3, were filled with 200 µl of bacterial suspension and incubated overnight at 
4ºC.  Wells were blocked for 1 hour at 4°C with blocking buffer (0.1M NaCO3 [pH 8.6], 




2.3   Selection of phage displayed peptides-biopanning 
Three biopanning protocols were evaluated for the selection of M. tuberculosis 
(∆leu/∆pan) binding peptides.  A brief description of the three biopanning protocols is 




In Biopanning Protocol 1, for the first round of panning, 10 µl of the library (~2 × 1011 
phages) was diluted to 100 µl with Tris-buffered saline supplemented with 0.1% Tween-
20 (TBST) (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% tween) and incubated in 
bacteria-coated polystyrene petri dish wells for 1 h at room temperature with gentle 
agitation.  Nonbinding phages were then discarded and the wells were washed 10 times 
with 200 µl of TBST.  Finally, the elution of the bound phage was carried out using 100 
µl the low-pH elution buffer (0.2 M Glycine-HCl [pH 2.2]).  The eluent was then 
neutralised with 15 µl of 1 M Tris-HCl [pH 9] and amplified by infecting its bacterial 
host E.coli ER 2738.  In the following rounds of biopanning an average of 2 × 1011 
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plaque-forming units (PFU) of the amplified phage from the preceding selection round 
was used.  After the three rounds of biopanning, the phage pools from the final round 
were assessed for binding to the targeted M. tuberculosis (∆leu/∆pan) and a related non-




Biopanning Protocol 2 was a solution-based panning. Similar to biopanning protocol 1, 
in the first round 10 µl of the library (~2 × 1011phages) was diluted to 100 µl with 
TBST.  The phage suspension was subsequently incubated in a micro centrifuge tube 
with 100 µl of M. tuberculosis (∆leu/∆pan) culture that was suspended in PBS (0.01 M 
phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride [pH 7.4]). 
The mycobateria and phage complex were collected by centrifugation (5 min, room 
temperature, 16,000 × g) and nonbinding phages discarded.  Mycobacteria were washed 
ten times with 200 µl TBST, by centrifugation (5 min, room temperature, 16,000 × g). 
The elution of the bound phage was performed by combining three elution fractions.  
The first fraction was carried out using 100 µl of the low-pH elution buffer (0.2 M 
Glycine-HCl [pH 2.2]) and immediately neutralised with 15 µl of 1 M Tris-HCl [pH 9]. 
This was followed by a 200 µl TBST wash and an additionalelution with 100 µl of the 
low-pH elution buffer.  All three elution fractions were combined after each round, 
amplified, tittered and 2 × 1011 PFU were used as input phage for the following round. 
After the three rounds of biopanning, the phage pools from the final round were assessed 
for binding to the targeted M. tuberculosis (∆leu/∆pan) strain and a related non-
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Biopanning Protocol 3 was a solid surface-based panning.  In the first round of panning, 
10 µl of the library (~2 × 1011 phages) was diluted to 100 µl with phosphate buffered 
saline supplemented with 0.1% Tween-20 (PBST) (0.01 M phosphate buffer, 0.0027 M 
potassium chloride and 0.137 M sodium chloride, pH 7.4, 0.1% Tween) and incubated in 
bacterial-coated MaxiSorp™ surface microtiter plate wells for 1 h at room temperature 
with gentle agitation.  Nonbinding phages were then discarded and the washes were 
performed as previously described(Lunder et al., 2008).  In brief, the wells were washed 
25 times with 200 µl of PBST followed by four washes with 200 µl of the low pH 
elution buffer (0.2 M Glycine-HCl, pH 2.2).  Finally, the elution of the bound phage was 
carried out using 100 µl of the low-pH elution buffer and sonicated in a sonicator water 
bath (50 kHz) for 10 minutes.  The eluent was then neutralised with 15µl of 1 M Tris-
HCl [pH 9].  In the following rounds of biopanning an average of 2 × 1011 PFU were 
used.  Five rounds of biopanning were performed.  The first three rounds were targeted 
against M. tuberculosis (∆leu/∆pan) and the phage eluates from round 3 were assessed 
for binding to the targeted M. tuberculosis (∆leu/∆pan) and compared to biopanning 1 
and 2 phage eluates.  Subsequently, round 3 was followed by a subtraction round against 
M. smegmatis.  The fifth round of positive selection was again against the targeted M. 
tuberculosis (∆leu/∆pan).  After the final round of biopanning, the phage eluates from 
round 5 were assessed for binding to the targeted M. tuberculosis (∆leu/∆pan) and two 
other mycobacteria species, namely M. smegmatis and BCG.  In addition to binding 
analysis, the unselected library, round 3, round 4 and round 5 phage eluates were also 
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2.4   Phage Amplification 
Phage eluates were amplified according to the suppliers’ instructions (New England 
Biolabs, MA, USA).  In brief, the phage eluates were used to infect an early log phase 
growing culture of E. coli ER2738 host cells.  After 4.5 h of growth at 37°C, bacteria 
were removed by centrifugation (10 min, at 4ºC, 12,000 × g) and phages in the 
supernatant were precipitated by adding one-sixth volume of 20% polyethylene glycol-
8000 and 2.5 M NaCl overnight at 4°C.  The precipitate was resuspended in 100 µl of 
PBS, and amplified eluates were titered according to the suppliers (New England 




2.5   Phage ELISA 
MaxiSorp™ surface microtiter plate wells (Nunc, Roskilde, Denmark) were coated with 
100 µl of mycobacteria suspension, with an optical density of 1.0 at 660 nm in carbonate 
buffer (35 mM NaHCO3, 15 mM Na2CO3 [pH 9.8]), and incubated overnight at 4ºC.  
Plates were blocked overnight at 4°C with blocking buffer (0.1M NaCO3 [pH 8.6], 
5mg/ml bovine serum albumin (BSA)).  A separate set of wells were blocked with 
blocking buffer without previous mycobacteria immobilization as negative controls (no 
target control).  The required concentration of each amplified phage eluate was 
resuspended in PBS to the final volume of 100 µl and transferred to the coated wells.  
The bacteria and phage eluates were incubated for 1.5 h at room temperature.  Wells 
were then washed six times with 200 µl of PBST.  Horseradish peroxidase (HRP)-
labelled mouse anti-M13 monoclonal antibody (Amersham Biosciences, Amersham, 
UK) was diluted in PBS (1:5,000).  Two hundred microliters of the antibody was added 
per well and incubated for 1 h at room temperature.  This was followed by washing of 
the wells six times with PBST.  One hundred and fifty microliters of substrate solution 
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(2,2'-azino-di-[3-ethylbenzthiazoline sulfonate] diammonium salt) (Thermo Scientific, 
MA, USA) was added and incubated for 30 min at 37°C.  The reaction was stopped with 
100 µl of 1% SDS.  Absorbance was determined using a Multiskan GO microplate 




2.6   Phage DNA preparation  
The amplification of the displayed peptides was performed with PCR using primers 
spanning the variable region in the gp3 phage coat protein (Appendix table 1).  Two 
sequencing reads were performed during Illumina sequencing.  The forward primer 
(Illumina_R1) contained the sequencing region for Illumina read 1 sequencing 
(Oligonucleotide sequences © 2006-2008 Illumina, Inc.) and was the same for all the 
phage DNA amplifications.  The reverse primers (Illumina_F1-F5) contained a 
homology sequence required for annealing to the Illumina sequencing flow cell, a 
sequencing region for Illumina read 2 sequencing and a six-nucleotide barcode to enable 
multiplexing (Oligonucleotide sequences © 2006-2008 Illumina, Inc.).  This enabled 
amplicons to be directly sequenced on an Illumina Genome Analyzer II as previously 
described (Griffin et al., 2011).  The PCR reaction mix consisted of 0.5 µM of each 
primer and 5U of the GoTaq® DNA polymerase mix (Promega, WI, USA) in a 100 µl 
final volume.  Whole phage PCR (denaturation at 95°C for 1 minute, annealing at 55°C 
for 2 minutes and extension at 72°C for 1minute and 30 seconds) was performed as 
previously described (Kingsbury and Junghans, 1995).  Cycles varied from 10 to 25, and 
the number of reaction tubes varied from 2 to 5, according to the amount of amplicon 
available for each sample.  The amplicons were analysed on a 2% agarose gel.  To 
validate the incorporation of the Illumina adaptor sequences, the PCR amplicons were 
cloned into a pGEMT-Easy cloning kit (Promega, WI, USA) according to the 
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manufacturer’s instruction.  Four to five clones were randomly selected from each pool 




2.7   Phage DNA high throughput sequencing using Illumina technology 
DNA Amplicons resulting from the PCR (0.45–0.85 µg) were sent to the department of 
computer science (Texas A&M University, Texas, USA) for DNA sequencing and 
analysis. The DNA was sequenced using the Illumina Genome Analyzer II.  The 
nucleotide sequence of the amplified region of the phage pIII protein (gp3) gene was 
reconstructed by aligning and combining the two paired-end reads.  The 36 bp (X12 
library) and 21 bp (X7 library) variable region was extracted by trimming off constant 
bases and was translated into amino acid sequences of length 12 using the Illumina GA 




3.0   Results 
 
3.1   Selection of phage displayed peptides that bind to intact M. tuberculosis 
 
In order to identify phage displayed peptides that bind to intact M. tuberculosis, a 12-
mer (X12) and a constrained 7-mer (CX7C) phage library were used for biopanning on 
immobilised M. tuberculosis (∆leu/∆pan).  This non-pathogenic auxotrophic M. 
tuberculosis (∆leu/∆pan) strain was used as a model organism because it can be 
grownoutside a biosafety level 3 laboratory but will have a cell wall equivalent to 
pathogenic M.tuberculosis.  The basic protocol for biopanning is described in chapter 1 
(section 1.5.4).  I initially tested three biopanning protocols using the CX7C phage 
library (Table 2.1).  The protocols tested varied in the strategies for immobilisation of 
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the target, stringency of the washing step and the elution of bound phages.  Three 
positive rounds of selection were performed and the resulting phage eluates were 
evaluated for binding to the target, M. tuberculosis (∆leu/∆pan) and a related non-




3.1.1  Biopanning Protocol 1 
The biopanning protocol 1, was a solid surface panning experiment which was 
performed according to the phage library manufactures instructions (New England 
Biolabs, MA, USA).  In brief, the M. tuberculosis (∆leu/∆pan) culture was immobilized 
directly on a plastic surface of a sterile polystyrene petri dish.  The conditions for the 
binding of the library to the target and the washes are detailed in section 2.3.  The 
elution strategy for biopanning protocol 1 involved a nonspecific disruption of the 
binding interaction between the phages and the target using a low pH buffer, 0.2 M 




Varying amounts of phages (2 × 105 PFU – 2 × 1011 PFU) from the final round of 
selection, round 3, were evaluated for binding to the targeted M. tuberculosis 
(∆leu/∆pan) and a related species of mycobacteria, M. smegmatis.  There was no 
significant difference between the binding signals of the selected pool of phages to both 
mycobacteria species when compared to the control wells which had no prior 
immobilisation of target (Figure 2. 1A).  This data is most likely indicative of an 
unsuccessful immobilization strategy employed during this protocol which was not 
suitable for mycobacteria resulting in the failure to immobilise mycobacteria during 
biopanning.  To overcome this limitation, a solution phase biopanning protocol was 
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evaluated in protocol 2.  In addition, the elution strategy used in this protocol was 
evaluated for efficiency before proceeding to protocol 2.  To evaluate the elution 
protocol, three elution fractions were collected (described in 2.3, biopanning protocol 2) 
and each fraction was titered to monitor the presence of phage in each fraction.  Phage 
was present in all three fractions tested for elution (Appendix figure 1).  This resulted in 
the adoption of a modified elution strategy for the biopanning protocol 2 where all three 
elution fractions were combined before phage amplification and used in the subsequent 




3.1.2  Biopanning Protocol 2 
To address the possibility that mycobacteria might not be efficiently immobilized on the 
polystyrene surface of the petri dish, a solution-phase panning protocol was used.  In 
brief, the phage library was allowed to react with the targeted mycobacteria in solution. 
The washing steps were performed under similar conditions to those used in protocol 1, 
with the exception of a low speed centrifugation step to recover the mycobacteria bacilli 




After three rounds of panning, a similar ELISA was used to access the level of 
enrichment during the selection.  There was a significant difference (p <0.01) between 
the binding signal of the selected pool of phages to both mycobacteria species when 
compared to the control wells which had no prior immobilisation of target (Figure 2. 
1B).  This result was the same when 2 × 108 PFU and 2 × 1011 PFU were used as input 
phages for the ELISA.  However, there was no significant difference in the binding 
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signal of the phage pools to mycobacteria when compared to the control wells when 2 × 




When comparing the binding of the selected phage population between the two 
mycobacteria species tested, there was no significant difference to the binding of the 
selected phage pool to the targeted M. tuberculosis (∆leu/∆pan) when compared to M. 
smegmatis (Figure 2. 1B).  Taken together, this data shows that the solution-phase 
biopanning protocol performed better in enriching for a phage population that binds to 
mycobacteria.  However, this protocol enriched for a population that did not 
discriminate between the targeted M. tuberculosis (∆leu/∆pan) and the related M. 
smegmatis, indicating that the elution protocol might have indiscriminately allowed for 
enrichment of phage clones that were common to the genus of mycobacteria.  To 
evaluate whether we couldperform a panning experiment that can enrich for M. 
tuberculosis species specific phage displayed peptides, we performed a third biopanning 





3.1.3  Biopanning Protocol 3: 
The biopanning protocol 3 was a solid surface panning experiment similar to protocol 1, 
with the exception that the M. tuberculosis (∆leu/∆pan) culture was immobilized directly 
on a pre-treated plastic surface with a high affinity for molecules with mixed 
hydrophilic/hydrophobic domains, namely the MaxiSorp™ plate (Nunc, Denmark).  
This immobilization protocol was performed mainly to improve the immobilization 
efficiency of mycobacteria on the solid surface and was previously demonstrated to be 
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effective when immobilizing mycobacteria by Stratmann and colleagues (Stratmann et 
al., 2002).  In addition, the washing protocol was made more stringent by increasing the 
number of washes using a similar tween supplemented buffer as forprotocol 1 and 2. 
Four additional washes were performed using a low pH buffer followed by sonication as 
previously described by Lunder and colleagues (2008).  Three positive rounds of 
panning were performed against the targeted M. tuberculosis (∆leu/∆pan).  When 
evaluating enrichment of target binding phages using a similar ELISA, our data showed 
that this protocol yielded a phage population that had a significantly higher binding 
signal when binding to M. tuberculosis (∆leu/∆pan) when compared to M. smegmatis or 
the control wells (Figure 2. 1C).  This observation was true when 2 × 1010 PFU were 
used as input, while there was no significant binding difference when 2 × 108 PFU or 
less was used.  This protocol was further used for a biopanning experiments starting 
with the X12 library and similarresults were obtained (Figure 2. 1D).  Taken together, 
our data indicated that the third biopanning protocol was more efficient in selecting 




Additional rounds of biopanning were performed to further enrich for M. tuberculosis 
(∆leu/∆pan) specific clones.  In brief, to remove peptides binding to cell wall 
components common to the mycobacteria genus, a subtraction round (round 4) was 
performed against M. smegmatis.  A final positive panning round (round 5) was 
performed to further enrich for peptides that were specific to M. tuberculosis 
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Table 2. 1:  Overview of Biopanning Protocols 
 
*Two additional panning rounds were performed on this protocol as detailed in figure 
2.2
Protocol Biopanning 1 Biopanning 2 Biopanning 3




Treated solid surface with





Washing step 10 X TBST (0.1% tween) 10 X TBST (0.1% tween) 25 X PBST (0.1% tween)
4X low pH glycine-HCl pH 
2.2 buffer
Elution strategy Low pH Low pH Low pH and sonication






1X Glycine-HCl pH 2.2
And sonication for 10 min
Number of selection 
rounds
3 3 3 *
The selection was considered successful when the average ELISA value of the selected pools binding to M. 
tuberculosis (∆leu/∆pan) significantly exceeded the binding to M. smegmatis after three rounds of 
selection.
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Figure 2. 1:  Binding comparison to mycobacteria of phages selected by different biopanning protocols using a whole cell ELISA assay 
Three biopanning experiments were performed against M. tuberculosis (∆leu/∆pan) and evaluated after three rounds of panning. Binding 
analysis to M. tuberculosis (∆leu/∆pan) and M. smegmatis of the final phage populations were performed and compared between the three 
biopanning protocols.  A two-tailed, unpaired t-test was used to analyse significance (NS = no significance, *p<0.05, **p<0.01). Error bars 









































































































































































Figure 2. 2:  Schematic oftreated solid phase biopanning strategy (protocol3) 
Three rounds of biopanning were performed against M. tuberculosis (∆leu/∆pan).  After the 
third round of panning, eluted phages were subjected to a subtraction round against M. 
smegmatis (round 4).  Round 5 was performed against the target M. tuberculosis (∆leu/∆pan).   
 
 
Ph.D unselected phage library
Immobilised M.tuberculosis
(∆pan/leu auxotroph) + bound 1011
phage from the unselected library, 
round 1 and round 2 respectively
Round 1-3
Subtraction round
Immobilised M.smegmatis + bound 
1011 phage from round 3
Round 4
Immobilised M.tuberculosis
(∆pan/leu auxotroph) + bound 1011










titered and used for round 5 
input phage
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3.2   Characterisation of the enrichment process from the biopanning protocol 3 using 
high throughput Illumina sequencing 
In order to evaluate the trend of enrichment during biopanning, we performed HTP sequencing 
on the naive phage library before selection and after three, four and five rounds of biopanning.  
The selected phage eluates were amplified by PCR.  The forward primer (Illumina_F1) for the 
PCR was the same for all phage amplification.  The primer sequence was adapted from the 
Illumina multiplexing PCR primer 1.01 (Illumina, 2006-2008) with an additional 33 bases 
homologous to gp3 region of the phage genome upstream of the random peptide insert.  The 
reverse primer (Illumina_R1-R8) sequences were adapted from the Illumina multiplexing PCR 
primer 2.01 (Illumina, 2006-2008) with an additional 18 bases homologous to the conserved 
phage sequence and a six base multiplex index tag which was unique for each phage pool.  All 




The PCR conditions are detailed in section 2.6.  Resulting amplicons were quantified and the 
expected size of approx. 200 bp was confirmed on a 2% agarose gel (Figure 2. 3A).  To 
validate the incorporation of the sequences needed for multiplexed Illumina sequencing, the 
PCR amplicons were cloned into a pGEMT-Easy vector.  Four to five clones were randomly 
sequenced (Inqaba Biotechnology, Pretoria, RSA) from each pool and their sequences were 
aligned with the corresponding primer pair and the multiplex index tag.  A representative 
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Illumina sequencing was then used to determine the unique sequences of the amplified phage 
inserts from each selection round.  The nucleotide sequences of the amplified region of the 
gp3 gene, was reconstructed by aligning and combining the two paired-end reads (Texas 
A&M University, Texas, USA).  The 36 bp variable region was extracted by trimming off 
constant bases and was translated into amino acid sequences using the Illumina GA Pipeline 




3.2.5  Characterization of CX7C biopanning enrichment 
Approximately 1.5 million sequence reads from each selection round were acquired during 
HTP sequencing.  This represented 1.36x106 unique peptides from the unselected library 
(Figure 2. 4A).  While this fell short of the theoretical complexity of the library, 1.23x109 
heptapeptides, it represented sufficient depth to measure the quantitative enrichment of 
relevant peptides.  To confirm successful enrichment during selection, we characterised the 
reduction in diversity of the phage eluates in the consecutive rounds of panning.  There was 
over two log reduction in the overall diversity of the phage eluates by the end of biopanning, 
in round 5 (Figure 2. 4A).  To illustrate, the number of unique sequences decreased from 
1,361,688 in the unselected library to 5665 after the final round of panning.  This is indicative 
of a successful selection for a subpopulation of phage clones during the biopanning 
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3.2.1 Characterization of X12 biopanning enrichment 
A similar number of sequence reads was obtained from each selection round of the X12 
biopanning when compared to the CX7C biopanning experiment.  This represented 0.73x10
6 
unique peptides in the unselected library (Figure 2. 4B).  While the theoretical complexity of 
this library is 4.1 x1015 dodecapeptides, the X12 phage library used for this study had an initial 
complexity in the order of 109, representing less than one millionth of the possible 
dodecapeptides.  Taking this into consideration, the sequencing depth achieved by the HTP 
experiment represented sufficient depth to measure quantitative enrichment of relevant 
peptides from this library.  Importantly, there was over one log reduction in the sequence 
diversity after three rounds of positive selection, while additional rounds of selection did not 
further reduce the diversity of the enriched pool (Figure 2. 4B).  A similar trend was also 
evident for the CX7C selection.  This suggests that for both selections, additional rounds of 
panning, round 4 and 5, did not have a dramatic effect on enrichment. 
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Figure 2. 3:  PCR amplification of phage inserts from the CX7C and X12 library pools.  
(A) PCR products from phage library insertsamplified using primers containing HTP Illumina adaptor sequences and multiplexing 
tags and visually evaluated on a 2% agarose gel.  (B) DNA alignments of sequences obtained from four clones picked from the X12 
library and subjected to amplicon sequencing using primer sets designed for HTP sequencing.  Sequence alignment of the forward 
and reverse primer sequences confirms the presence of the Illumina adaptor sequences, while the alignment of the unique multiplex 
tag was also confirmed for each round of selection. 
A
B




Figure 2. 4:  Sequence enrichment profiles 
Sequence enrichment profiles after high-throughput sequencing of the phage 
displayed libraries using Illumina technology.  Histograms of the number of unique 
peptides observed in the different rounds of biopanning from the (A) CX7C library 




3.3   Characterisation of the binding of the phage populations enriched 
during biopanning protocol 3 
To evaluate the effectiveness of the two additional rounds of biopanning, binding 
signals of round 3 and round 5 phage eluates were compared to each other using an 
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binding signal of the round 5 phage eluates to M. tuberculosis (∆leu/∆pan) 
compared to the phage pool from round 3 (Figure 2. 5A).  This indicates that the 
two additional rounds of biopanning resulted in the enrichment of M. tuberculosis 
(∆leu/∆pan) binding peptides.  Similar results were observed for the X12 biopanning 
experiment, showing a significant (p < 0.05) increase in binding signal to M. 
tuberculosis (∆leu/∆pan) of phage eluates from round 5 when compared to those 




To assess the effectiveness of the subtraction round, round 4 against M. smegmatis, 
binding signals of the phage eluates to M. smegmatis were assessed before and after 
the subtraction round.  Phage eluates from both libraries showed a significantly (p < 
0.01) higher binding signal to M. smegmatis after the subtraction round (Figure 2. 
5A-B).  This data indicates that the subtraction round was not successful in 
eliminating M. smegmatis binding phages.  Alternatively, it is possible that the 
majority of the phage clones in round 5 bind to a common surface exposed 




To verify possible promiscuous binding of the selected phage populations to 
members of the Mycobacterium genus, we tested whether a similar pattern of 
increased binding was observed with BCG, which is another related species of M. 
tuberculosis (∆leu/∆pan).  Indeed, for both libraries, the phage eluates from round 5 
showed a significant increase (p < 0.01) in binding to BCG when compared to 
round 3 phage eluates (Figure 2. 5A-B).  Taken together, this data suggests that 
thetwo additional rounds during biopanning protocol 3 enriched for a population of 
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phage clones that potentially bind promiscuously to the surface of bacteria 




Figure 2. 5: Comparison between the binding of the phage eluates before and 
after the subtraction round using ELISA 
Binding analysis to M. tuberculosis (∆leu/∆pan), M. smegmatis and BCG, of the 
round 3 and round 5 phage eluates from the (A) CX7C and (B) X12 biopanning 
experiments.  A two-tailed, unpaired t-test was used to analyse significance 
(*p<0.05, **p<0.01). Error bars represent standard deviations of the arithmetic 
means of optical densities at 405 nm measuredin triplicates, which were normalised 
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3.4   Binding of the enriched phage eluates to mycobacteria cultured under 
different conditions 
A previous finding showed that mycobacteria cultured in the absence of detergent 
and agitation have a thick outermost capsule-like layer, while those grown under 
the traditional laboratory conditions in the presence of both detergent and agitation 
have this layer partially or completely removed (Sani et al., 2010).  To 
determinewhether the selected phage population binding is affected by the presence 
of the capsular layer in mycobacteria, the final pool of phages wastested for 
itsability to bind mycobacteria when it is grown under these two different culturing 
conditions.  The phage eluate from round five of both the CX7C and X12 biopanning 
experiments showed no significant difference in binding to M. tuberculosis 
(∆leu/∆pan) when grown under both conditions (Figure 2. 6A-B).  However, for 
both libraries,  there was a significantly higher binding signal of the final phage 
pool to M. smegmatis (p < 0.01) and BCG (p < 0.05) when grown in the absence of 
detergent and agitation as compared to the traditional laboratory culturing 
conditions that include detergent and agitation (Figure 2. 6A-B).  Taken together, 
these results show that the selected population of phages is able to bind 
mycobacteria grown under both conditions.  However, for both libraries the binding 
of the final phage eluates to M. smegmatis and BCG is enhanced by the presence of 
the capsule-like layer, while the binding to M. tuberculosis (∆leu/∆pan) is not 










Figure 2. 6:  Binding of the phage eluates from round 5 to mycobacteria grown 
under different culturing conditions using ELISA 
Phage eluates from the final round of selection of the (A) CX7C and (B) X12 
biopanning experiments were amplified and 5×1011 PFU were used for a plate 
binding assay with M. tuberculosis (∆leu/∆pan), M. smegmatis and BCG as solid-
phase antigens.  A two-tailed, unpaired t-test was used to analyse significance (NS 
= no significance, **p<0.01, *p<0.05).  Error bars represent standard deviations of 
the arithmetic means of optical densities at 405 nm performed in triplicates, which 
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4.0   Discussion 
 
Phage display technology has made it possible to search for peptides that bind to 
various protein (Koivunen et al., 1994, Pasqualini et al., 1995) and non protein 
targets, like silica (Naik et al., 2002) and apatite-based material (Segvich et al., 
2009).  In this study, I applied phage display technology with the aim of 
identifyingpeptide ligands that bind to M. tuberculosis.  I evaluated three 
biopanning protocols varying mainly in immobilisation of the target, stringency in 
the washing steps of unbound phages as well as elution of the bound phage 
strategies. The data showed that immobilisation of mycobacteria on the Maxisorp™ 
surface, which has a high affinity to molecules with mixed hydrophilic and 
hydrophobic domains, performed better when compared to untreated surfaces. 
While the solution based panning yielded the highest binding signal of the phage 
eluates, the final phage population failed to discriminate binding between M. 
tuberculosis and M. smegmatis after three rounds of biopanning.  This is likely due 
to the extensive elution method adopted for this panning protocol, which combined 
three elution fractions of the bound phage.  While this elution method achieved the 
enrichment of mycobacteria binding phage clones, these phage clones were non-
discriminating, possibly binding to surface components that are common among 
mycobacteria species.  Taken together, thefindings indicate that biopanning 
protocol 3 was the best suited protocol for selecting phage displayed peptides 




Traditionally, the success of a biopanning experiment is confirmed by evaluating 
the binding affinity of randomly picked clones to the target.  While this method 
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usually leads to the identification of phage displayed peptides that bind to their 
target, it falls short in describing the global enrichment trend during biopanning as 
well as identifying the most enriched clones which are likely to be peptides with the 
best binding affinities to the target.  HTP sequencing has made possible the 
sequencing of millions of inserts allowing for a higher resolution of the selected 
pool of the displayed peptides.  In this study we used both a binding assay and HTP 
sequencing to validate the success of the selected panning protocol.  The higher 
resolution of the selection pools enabled us to demonstrate the reduction in the 
number of unique peptides during biopanning, which is indicative of the 
enrichment of a subset of phages.  The HTP sequencing results correlated with the 
binding assay of the selected phage population to the targeted M. tuberculosis 
(∆leu/∆pan), which showed an increased binding of the phage pools at the end of 
selection when compared to the phage pools at round 3.  Surprisingly, the 
additional subtraction round against M. smegmatis did not result in the exclusion of 
M. smegmatis binding phage clones.  As a result, theenriched phage population is 
likely composed of phage clones that bind to surface molecules conserved across 
the three mycobacterium species.  This data is indicative of the invariable nature of 





Recently, Sani and colleagues (2010) demonstrated the presence of the labile 
capsular layer that covers the outer membrane of both pathogenic and non 
pathogenic mycobacteria.  They further showed that the capsular layer is influenced 
by the culturing conditions used in the laboratory which involve detergent and 
agitation, resulting in the shedding of the capsule into the medium.  The capsular 
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layer is known to be composed of polysaccharides, proteins and small amounts of 
lipids (Daffe and Etienne, 1999, Lemassu et al., 1996, Ortalo-Magne et al., 1995). 
Sani and colleagues (2010) showed that the detection of these components, namely 
the major capsular polysachharide (α-glucan), the glycolipid phosphatidylinositol 
mannosides (PIMs) as well as the EspE protein associated with the capsule, was 
weaker when mycobacteria is grown with agitation.  Since our biopanning 
experiments were performed on M. tuberculosis (∆leu/∆pan) cultures grown under 
the conventional laboratory conditions, we investigated whether the presence of the 
capsule affected the binding of the enriched phage population.  We had 
hypothesised that, if the phage eluates has a common binding partner amongst the 
different mycobacteria species, the binding trend will be similar between species. 
Surprisingly, binding of the phage to M. tuberculosis (∆leu/∆pan) was not affected 
by the presence of the capsule while binding to both M. smegmatis and BCG was 
enhanced.  This result possibly indicates a different binding partner on the cell 
surface of M. tuberculosis (∆leu/∆pan) that is not affected by the presence of the 
capsular layer.  Alternatively, it is possible that the non pathogenic M. tuberculosis 
(∆leu/∆pan) strain is not able to form a capsular layer under the tested conditions. 
Taken together, these results suggest that the enhanced binding of the phage pool to 
M. smegmatis and BCG when the capsular layer is present is likely a result of the 




In conclusion, we demonstrated the selection of a binding population of phage 
clones against M. tuberculosis (∆leu/∆pan) using a Maxisorp™ surface based 
biopanning protocol with the modified washing and elution strategy.  We further 
demonstrated that the presence of the capsular layer on mycobacteria does not 
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diminish the binding of the phage pools to mycobacteria.  However, in the case of 
M. smegmatis and BCG the binding is enhanced by the presence of the capsular 
layer.  Notwithstanding, this protocol sufficed to allow for the identification of 

























CHARACTERISATION OF A HIGHLY ENRICHED PHAGE CLONE 





















At the end of a successful biopanning experiment, the discovery of the highly 
enriched clones or strong binders remains a challenge.  Traditionally, the random 
clone-picking method is used to identify phage displayed peptides that were 
enriched during biopanning.  However, depending on the sequence diversity at the 
end of the selection, this method may not necessarily identify the highestenriched 
clones.  High-throughput (HTP) sequencing has now made it possible to sequence 
millions of inserts enabling a more quantitative approach to the identification of 
highly enriched clones resulting from a biopanning experiment.  In this chapter, I 
used both the traditional random clone picking method and high throughput 
sequencing, to identify the highly enriched clones during biopanning.  The most 
highly enriched phage (clone 1), displaying the CPLHARLPC peptide, was only 
identified by Illumina sequencing but not by random clone picking.  This phage 
clone is able to bind mycobacteria significantly better than the unselected phage 
library.  Surface plasmon resonance showed that the chemically synthesised 
CPLHARLPC peptide binds M. tuberculosis H37Rv after bacterial lysis and does 
not bind to non-mycobacteria lysates.  Furthermore, the target for the phage 1 
displayed peptide was characterised to be a mycobacteria protein of about 15 kDa 
in size.  These observations demonstrate that phage display technology combined 
with high-throughput sequencing is a powerful tool to identify peptides that can be 
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1.0   Introduction 
 
Short peptides identified from a phage display library have been previously used in 
a capture PCR to detect M. paratuberculosis from milk of infected dairy herds 
(Stratmann et al., 2002).  This study aimed to identify phage clones that bind 
specifically to M. tuberculosis or mycobacteria.  These clones could subsequently 
be used to probe for its target in patients’ clinical samples and ultimately identify a 




However, one of the challenging steps in the use of phage display technology is the 
identification of the most promising candidates at the end of the biopanning 
experiment.  While the random clone picking method is commonly used for the 
identification of the highest enriched clone during biopanning, it falls short of 
providing a sequencing depth that can enable a global evaluation of the enriched 
phage population.  However, with the availability of HTP sequencing it is now 
possible to sequence millions of inserts displayed by the enriched phage population, 
allowing for a higher resolution of the selected pool of the displayed peptides.  
Thus, we employed both the traditional clone picking method together with HTP 
sequencing to identify highly enriched phage clones during biopanning. 
Surprisingly, we found that the most abundant phage clone, as identified through 
HTP sequencing, was missed by the traditional clone picking method.  The 
identified clone was further characterised for binding specificity to mycobacteria 
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2.0   Materials and Methods 
 
The bacterial strains used, their growth conditions, immobilisation of target 
mycobacteria, phage amplification, phage ELISA and phage DNA preparation and 




2.1   Phage 1 DNA amplification and sequencing 
The DNA sequence which encoded for the phage displayed peptide was amplified 
by phage colony PCR.  The primer pair sequences, forward (Find_Phage1_F1) and 
reverse primer (Find_Phage1_R1) are listed in Appendix table 1.  The PCR reaction 
mix consisted of 0.5 µM of each primer, 200 µM of each dNTP, 1.5 mM MgCl2,  
1 × DNA polymerase buffer (Promega, WI, USA) and 5U of the GoTaq® DNA 
polymerase mix (Promega, WI, USA) in a 100 µl final volume.  Whole phage PCR 
(denaturation at 95°C for 1 minute, annealing at 55°C for 2 minutes and extension 
at 72°C for 1minute and 30 seconds) was performed as previously described 
(Kingsbury and Junghans, 1995).  Thirty PCR cycles were performed.  The 
resulting amplicons were separated on a 2% agarose gel.  Three insert positive 
clones were randomly selected and sequenced.  The sequencing results were 
compared to the phage sequences obtained from HTP Illumina sequencing, and the 
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2.2   Mycobacteria specificity phage ELISA for the Illumina identified 
enriched clones 
Microtiter plate wells were coated with 100 µl of mycobacteria suspension per 
well, with an optical density of 1.0 at 660 nm in carbonate buffer (35 mM 
NaHCO3, 15 mM Na2CO3 [pH 9.8]), and incubated overnight at 4ºC.  A separate 
set of wells were blocked with blocking buffer without previous mycobacteria 
immobilization as negative controls (no target control).  Plates were blocked 
overnight at 4°C with 200 µl of the gelatin (0.5%)-supplemented supernatant of an 
E. coli strain ER2738 F´ culture infected with the whole phage library.  Each 
concentration of the selected and amplified phage clone was made up to one 
hundred microliters in PBS andtransferred to coated wells.  Plates were incubated 
for 1.5 h at room temperature.  Wells were then washed six times with PBST.  
Horseradish peroxidase (HRP)-labelled mouse anti-M13 monoclonal antibody 
(Amersham Biosciences) was diluted in PBS (1:5,000).  Two hundred microliters 
of the antibody was added per well and incubated for 1 h at room temperature.  This 
was followed by washing the wells six times with PBST.  One hundred and fifty 
microliters of substrate solution (2,2'-azino-di-[3-ethylbenzthiazoline sulfonate] 
diammonium salt) (Thermo Scientific) was added and incubated for 30 min at 
37°C.  The reaction was stopped with 100 µl of 1% SDS and absorbance recorded 




2.3   Peptide Synthesis 
Both peptides (Biotin-ACPLHARLPCG and its scrambled derivative Biotin-
ACHLRPPLACG) were synthesised by GL Biochem (Shanghai, China), with the 
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2.4 Surface plasmon resonance (SPR) biosensor analysis 
A Biacore™ 3000 instrument (GE Healthcare UK Ltd, Buckinghamshire, England) 
was used for SPR measurements.  Instrument temperature was set to 25ºC and 
HBS-N (10 mM Hepes and 150 mM NaCl, [pH 7.4]) was used as running buffer.  
50 µg/ml (80 µl) of streptavidin, in sodium acetate buffer [pH 4.5], was 
immobilised by amine coupling on the CM5 sensor chip (GE Healthcare UK Ltd, 
Buckinghamshire, England).  Immobilisation was performed at a flow rate of 
10µl/min for 7 min.  The biotinylated peptides were captured using the previously 
immobilised streptavidin.  A total of 60 µl of 100 µg/ml biotinylated-peptide in 
PBS (sample flow cell) was loaded onto the chip at the flow rate of 10 µl/min.  No 
streptavidin or peptide was immobilised on the negative control flow cell.  Binding 
of whole cell lysates to the biotinylated peptide was then analysed by diluting the 
lysate in HBS-N buffer (10 mM Hepes and 150 mM NaCl, [pH 7.4]) and passing it 
over the chip at 10 µl/min.  The M. tuberculosis H37Rv whole cell lysate binding 
was analysed at concentrations of 100 and 500µg/ml of total protein, while the 





2.5 Protease digestion of M. tuberculosis H37Rv lysate 
M. tuberculosis H37Rv whole cell lysate (BEI Resources, VA, USA) was treated 
with 1 mg/ml Pronase E (Sigma, St. Louis, MO) for 2 hours.  The protease 
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digestion reaction was inactivated by heating at 90ºC for 20 minutes.  The negative 




2.6 Pull-down assay 
Biotinylated peptides (60 µl; 1 mg/ml) were captured on 100 µl of streptavidin 
conjugated beads (Resyn Biosciences, Pretoria, Republic of South Africa).  Two 
washing buffers, PBS and the same buffer with additional 0.5 M NaCl, were used 
during the experiment.  The beads were washed three times with the relevant 
washing buffer prior to incubation with the M. tuberculosis H37Rv lysate.  
Subsequently, the streptavidin beads were mixed with 500 µg total proteins of M. 
tuberculosis H37Rv whole cell lysate.  The final volume was adjusted to 500 µl 
with PBS and the mixture was placed on a rotating shaker with gentle mixing at 
4ºC for 16 hours.  Following incubation, the beads were pelleted using a magnet 
and the supernatant removed.  The beads were washed three times each with 1 ml 
of the respective wash buffer.  After the last wash, the pulled down mixture was 
resuspended in 50 µl of Laemmli sample buffer (63 mM Tris HCl [pH 6.8], 10% 
Glycerol, 2% SDS, 2% (v/v) 2-mercaptoethanol, 0.1% (w/v) Bromophenol Blue), 
denatured at 95ºC for 5 min, separated by electrophoresis onto a 12% SDS–




2.7   SDS PAGE gel analysis 
The 12% SDS/PAGE gel was used which was comprised of a stacking gel of 4% 
(w/v) acrylamide and a separating gel of 12% (w/v) acrylamide.  Gel 
electrophoresis of samples was carried out at 180V for 1 hour.  
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2.8   Liquid chromatography-tandem mass spectrometry LC-MS/MS analysis 
Protein bands of interest were in-gel trypsin digested as described in (Shevchenko 
et al., 2006).  In short, protein bands were destained using 50mM NH4HCO3/50% 
CH3OH followed by in-gel protein reduction (50mM DTT in 25 mM NH4HCO3) 
and alkylation (55 mM iodoacetamide in 25 mM NH4HCO3).  Proteins were 
digested over night at 37°C in 5 – 50 µl of 10 ng/µl tryspin depending on the gel 
piece size.  Peptides were extracted using 50% acetonitrile (ACN)/5% formic acid 




Samples were re-suspended in 35 µl 2% ACN / 0.2% FA and analysed using a 
Dionex Ultimate 3000 RSLC system coupled to a QSTAR ELITE mass 
spectrometer.  Peptides were first de-salted on an Acclaim PepMap C18 trap (75 
µm x 2 cm) for 8 min at 5 µl/min using 2 % ACN/0.2 % FA, then separated on 
AcclainPepMap C18 RSLC column (75 µm x 15 cm, 2 µm particle size) connected 
to the trap column via a 10-port switching valve.  Peptide elution was achieved 
using a flow-rate of 500 nl/min with a gradient: 4-60 % B in 30 min (B: 80% 
ACN/0.1 % FA).  Nano-spray was achieved using a MicroIonSpray head assembled 
with a New Objective, PicoTip emitter.  An electrospray voltage of 2.0 - 2.8 kV 
was applied to the emitter.  The QSTAR ELITE mass spectrometer was operated in 
Information Dependent Acquisition (IDA) using an Exit Factor of 2.0 and 
Maximum Accumulation Time of 2.5 sec.  MS scans were acquired from m/z 400 
to m/z 1500 and the three most intense ions were automatically fragmented in Q2 
collision cells using nitrogen as the collision gas.  Collision energies were chosen 
automatically as function of the mass of the ion (m) upon the charge (z) (m/z). 
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3.0   Results 
 
3.1   Identification and characterisation of selected clones 
Ten phage plaques from the final round of phage eluates were randomly selected 
and sequenced from each library.  In addition to the traditional random clone 
picking method used to identify enriched peptides, high throughput Illumina 
sequencing was performed as described in chapter 2 (section 2.6) and used to 




3.1.1  CX7C randomly selected phage clones 
Three unique sequences, namely phage 2, 3, and 4, were obtained from the six 
successfully sequenced randomly selected plaques (Table 3. 1).  Two clones, phage 
3 and phage 4, were represented more than once (Table 3. 1).  HTP sequencing, 
however, described a different quantitative landscape.  HTP sequencing identified 
phage 1 as the most abundantly enriched clone, which was not identified using 
random clone picking.  Phage 1 represented more than 80% of the enriched phage 
population as early as round three of biopanning.  Nonetheless, there is some 
degree of correlation between the peptide sequences that were identified by 
traditional clone picking and the top five sequences identified using high-
throughput sequencing.  That is, all three unique sequences identified during 
random clone picking were in the top five of the most abundant peptides identified 
by HTP.  Moreover, since the most abundant peptide had a frequency of more than 
80% after the first three rounds of selection, this means that with the current 
sequencing depth, further rounds of selection will less likely have lead to the 
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To establish whether the selected peptides were not binding to non-targeted 
substrates and/or other components used during the biopanning process like BSA, 
we used the free web tool for scanning, reporting and excluding possible target-
unrelated peptides from real binding peptides.  This tool is called the Scanner and 
Reporter Of Target-Unrelated Peptides (SAROTUP) (Huang et al., 2010).  None of 
the four sequences selected were identified as non-specific binders.  However, the 
SAROTUP web server indicated that the phage1 displayed peptide has been 
previously isolated against an antibody targeting  the surface haemagluttinin protein 




3.1.2  X12 randomly selected phage clones 
Sequencing data from the ten randomly selected clones identified six unique 
sequences, namely phage 5, 6, 7, 8, 9 and 10 (Table 3. 1), while sequencing of one 
plaque was unsuccessful.  Two clones, phage 9 and phage 10, were represented 
more than once (Table 3. 1).  There was a good degree of correlation between the 
peptide sequences that were identified by traditional clone picking and the top 
fivesequences identified using high-throughput sequencing.  That is, all the 
randomly selected clones with the exemption of phage 6, were also identified in the 
top ten identified by high-throughput sequencing.  In constrast to CX7Cbiopanning 
which resulted in an enrichment of a single peptide to levels higher than 80% of the 
final phage population, for X12 biopanning, none of the peptides were enriched to 
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levels higher than 12% of the total sequenced population.  This means that with the 
current sequencing depth, further rounds of selection could have possibly led to 




The six clones identified using HTP were scanned on the SARUTOP web server for 
non target related binding.  Similar to the CX7C sequences, none of the six 
sequences selected were identified as nonspecific binders using the SAROTUP web 
server.  However, the peptide displayed by phage clone 7 has been previously 
isolated against several targets (Cao et al., 2011, Carter et al., 2006, Dickerson et 
al., 2008, Ejima et al., 2010, Estephan et al., 2009, Hardy et al., 2007, Kim et al., 
2010, Mohammadi et al., 2007, Rothenstein et al., 2012, Roy et al., 2008, Sawada 
et al., 2011, Tipps et al., 2010, Yang et al., 2010, Zhao et al., 2010) indicating that 
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aClones identified in the top ten highly enriched sequenced by HTP sequencing 
bClones identified through random sequencing 










SAROTUP: Target Unrelated 
Peptide scanner for other targets
Random picking 
at round 5
HTP sequencing at 
round 5
n                % n                    %
CX7C 1
a† 6                 0 1 655 954           82.49 CPLHARLPC Anti-influenza A H1N1 monoclonal 
antibody IV.C102 and SIV sera from 
patients (Zhong et al., 2011)
2a,b 6              16.67 1 655 954           0.81 CHYDGARAC None found
3a,b 6              33.33 1 655 954           0.92 CDHGYLPSC None found
4a,b 6              50.00 1 655 954            5.05 CFDTRSLVC None found
X12 5
a,b† 9             11.11 1 467 822            9.17 YMPNPFTASKWK None found
6a 9             11.11 1 467 822         Not
detected
YYNNPLLISRLP None found
7a 9 11.11 1 467 822          11.93 LLADTTHHRPWT Protein tonB (Carter et al., 2006), 
Umbilical endothelial cells (Hardy et 
al., 2007), Anti-MUC1 monoclonal 
antibody PR81(Mohammadi et al., 
2007), Semiconductor crystalline 
surface ZnSe (Estephan et al., 2009), 
Bevacizumab-treated tumor
vasculature in nude mice (Cao et al., 
2011), Mouse embryonic stem  cells 
(Zhao et al.), Glycine receptor subunit 
alpha-1(Tipps et al., 2010), Anti-
EGFR monoclonal antibody 12H23 
(Yang et al., 2010), Hyperbranched
poly(phenylene vinylene) (Ejima et 
al.), In vitro M cell co-culture system 
(Kim et al.), Solubilizedmatrices 
(Integra ®) (Sawada et al., 2011), 
Hydroxyapatite, HA(Roy et al., 2008), 
titania (TiO2) (Dickerson et al., 2008), 
Oxygen-terminated sides of single-
crystalline ZnOand Zinc-terminated 
sides of single-crystalline ZnO
(Rothenstein et al., 2012). 
8a 9             11.11 1 467 822           2.31 DLHPRRPPTIHD None found
9a 9 22.22 1 467 822            1.53 SITYMHHQPQKY None found
10a 9             33.33 1 467 822             6.46 YPAPQPLVTKTS None found
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3.2   Binding characterisation of the randomly selected recombinant phages 
Binding of the randomly selected phage clones was investigated using an 
immobilised M. tuberculosis (∆leu/∆pan) strain (Figure 3.1A).  All the randomly 
selected clones binding signal to M. tuberculosis (∆leu/∆pan) was significantly 
higher (p < 0.01) than the assay negative control without phage input (Figure 3.1).  
While there was no significant difference in the binding signal to M. tuberculosis 
(∆leu/∆pan) amongst all the phage clones identified from the X12 biopanning, 
phage 3 and 4 from the CX7C biopanning bound M. tuberculosis (∆leu/∆pan) with 
a significantly higher binding signal (p<0.05) when compared to phage 2 which 




To evaluate the specificity of the selected phages, their binding to M. tuberculosis 
(∆leu/∆pan) was compared to their binding to M. smegmatis and BCG (Figure 3.1 
B-C).  All the clones binding signal to both BCG and M. smegmatis was higher 
than the negative control.  However, there was no significant difference in binding 









Figure 3. 1:  Binding of the randomly selected phage clones to mycobacteria 
using an ELISA 
Binding of the individual phages to (A) M. tuberculosis (∆leu/∆pan), (B) M. 
smegmatis and (C) BCG as compared to the assay buffer control without phage 
input (negative control).  All values were normalised to wells without previous 
mycobacteria immobilization.  A two-tailed, unpaired t-test was used to analyse 
significance (**p<0.01).  Error bars represent standard deviations of the arithmetic 
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3.3   Identification of the highest enriched phage (clone 1) from CX7C 
biopanning 
PCR was used to recover phage 1, which HTP sequencing identified as the highest 
enriched clone.  A PCR primer pair was designed to specifically amplify the 
sequence encoding for the displayed peptide of phage 1.  The forward primer 
(Find_Phage1_F1) sequence washomologous to the gp3 region of the phage 
genome upstream of the random peptide insert, while the reverse primer 
(Find_Phage1_R1) was homologous to 15 bases which encoded for part of the 
displayed peptide.  Both primer sequences are listed in appendix supplementary 




The monoclonal phages(2 and 3) identified by random picking, were plated on LB 
agar plates and the phage clones used as input phage to demonstrate the specificity 
of the primer pair on a PCR assay as described in section 2.1 of this chapter.  There 
was no detectable amplification of the phage insert from both phage clones during 
the primer test PCR (Figure 3. 2A).  The phage population from the final round of 
the CX7C panning was alsoplated on LB agar plates and individual clones were 
used to screen for phage 1.  Ten phage clones were selected from the plated, final 
round of enriched phages and subjected to phage 1 specific colony PCR.  Six out of 
the ten phage clones were positive for amplification of the phage 1 random insert 
(Figure 3. 2B).  Three positive clones were sent for sequencing and all three 
resulting sequences were identical to the phage 1 sequence identified using Illumina 
sequencing.  One of the confirmed clones was amplified and titered for further 
characterisation. 
 





Figure 3. 2:  Colony PCR for the identification of phage 1 
 (A) The PCR prime pair (Find_Phage1_F1/R1) was tested for specificity using 
randomly picked phage 2 and phage 3 as amplicons.  No amplification was detected 
(-) for phage 1 insert. (B) Ten phage clonesfrom round 5 of CX7C biopanning 
phage population were tested for positive amplification using the 
Find_Phage1_F1/R1PCR primer pair for amplification of phage 1 peptide insert. 
(+) positive for phage 1 insert. 
A
B
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3.4   Binding characterisation of the highly enriched, HTP sequencing 
identified Phage 1 
The isolated highly enriched phage 1, was investigated for its ability to bind the M. 
tuberculosis (∆leu/∆pan) strain which was used during biopanning as well as 
binding to the pathogenic strain M. tuberculosis H37Rv, using ELISA.  Phage 1 
binding signal to both strains of mycobacteria was at least twice as high when 
compared to its binding to the unselected phage library which was used as a control 
(Figure 3. 3A-B).  However, there was no significant difference in binding the 
pathogenic strain M. tuberculosis H37Rv when compared to M. tuberculosis 
(∆leu/∆pan).  In addition, phage 1 was evaluated on its ability to discriminate 
between bacteria from the same genus of mycobacteria by comparing its binding to 
M. tuberculosis to two other mycobacteria species namely, M. smegmatis and M. 
bovis BCG.  Our results show that phage 1 consistently bound to all the three 
mycobacteria species with a binding signal similar to that of M. tuberculosis 
(∆leu/∆pan) which was targeted during panning.  That is, there was no significant 
difference in binding to all mycobacteria species tested.  These results were 









Figure 3. 3:  Characterisation of the HTP identified phage (clone 1) binding to 
mycobacteria 
Phage clone 1 (A-D) was amplified and 5×1011PFU and 1×1012 PFU were used for 
a plate binding assay with (A) M. tuberculosis H37Rv, (B) M. 
tuberculosis(∆leu/∆pan), (C)BCG and (D) M. smegmatis as solid-phase antigens.  
The unselected library was used as a control.  A two-tailed, unpaired t-test was used 
to analyse significance (**p<0.01).  Error bars represent standard deviations of the 
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3.5   Binding of the synthetic peptide displayed by phage 1 to M. tuberculosis 
H37Rv lysate 
In order to test whether the highly enriched displayed peptide can bind its ligand 
when it is not displayed by the carrier phage, the peptide displayed by phage 1, 
CPLHARLPC (phage1-synpeptide) and a scrambled derivative CHLRPPLAC 
(phage1-synpeptide-Sc) were synthesised with a biotinylation modification on the 
N-terminus.  The binding of the synthesised peptides to the whole cell lysate from 




Biotinylated peptides were immobilised on a streptavidin sensor chip (Figure 3. 
4A) and whole cell lysates were injected at different concentrations of total protein.  
When the peptide binding was measuredat 470 seconds after the start of lysate 
injection, there was a 7.1 fold increase in binding of the whole cell lysate to 
phage1-synpeptide at 100 µg/ml (Figure 3. 4B) as compared to the negative control 
which had no prior immobilisation of the synthesised peptides; and an even higher 
fold increase of 22.9 when the whole cell lysate concentration was increased to 500 
µg/ml (Figure 3. 4C).  The scrambled derivative had a fold increase of 3.8 
compared to the negative control, at the total protein concentration of 100 µg/ml 
and only increased to 7.1 fold when at 500 µg/ml of the total protein concentration.  
This data indicates that, Phage1-synpeptide has a stronger and more specific 




To further evaluate the binding specificity of the selected peptides to mycobacteria, 
their ability to bind to whole cell lysate from other unrelated bacteria was 
evaluated.  The tested bacteria included both Gram negative and Gram positive 
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bacteria that are potential upper respiratory tract pathogens and the E. coli strain 
used for the amplification of phage during biopanning.  Both the synthesised 
peptide and its scrambed derivative did not bind to any of the non mycobacteria 
lysates tested.  That is, all non mycobacteria lysates tested showed similar binding 
to the synthesised peptide, its scrambled derivative and the negative control (no 
peptide) flow cell (Figure 3. 4D-G).  This data suggests thatthe selected peptide 
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Figure 3. 4:  Sensograms showing the association of bacteria whole cell lysates 
with immobilized synthetic peptides using SPR Biacore™ 3000 
(A) Phage1 synthetic peptide (phage1-synpeptide) and scrambled peptide (phage1-
synpeptide-Sc) were captured with covalently bound streptavidin on a CM5 chip. 
No peptide was captured on the covalently bound streptavidin for the negative 
control.  Whole cell lysates of M. tuberculosis H37Rv with a total protein 
concentration of 100 µg/ml (B) and 500 µg/ml (C) were injected over the 
immobilised peptides. To evaluated specificity whole cell lysates with a total 
protein concentration of 100 µg/ml from unrelated bacteria, (D) Escherichia coli 
ER2738, (E) Corynebacterium xerosis, (F) Streptococcus pyogenes, (G) 
Staphylococcus aureus, were injected over the immobilised peptides.  Changes in 
surface plasmon resonance were monitored in real time and are shown in response 
units. 
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3.6   Characterisation of the mycobacteria cell wall associated binding 
partner for Phage1 synthetic peptide (phage1-synpeptide) 
To determine if the target of phage 1 displayed peptide on the surface of 
mycobacteria is a protein, we tested its binding to protease-treated M. tuberculosis 
whole cell lysate.  The digestion was performed as detailed in section 2.5 of this 
chapter.  Our results showed that the binding of phage1-synpeptide to M. 
tuberculosis whole cell lysate is abrogated after the lysate has been incubated for 2 
hrs with Protenase E (Figure 3.5A-B).  This data suggests that phage1-synpeptide 




In order to determine which mycobacteria protein interacts with the phage 1 
displayed peptide, we performed a pull down assay from M. tuberculosis H37Rv 
whole cell lysate using phage1-synpeptideas a capture peptide.  Two wash buffers 
were evaluated, namely PBS and a more stringent wash buffer which was PBS with 
a highersalt concentration of 0.5M NaCl.  The scrambled derivative, phage1-
synpeptide-Sc, and the streptavidin beads without prior immobilisation of the phage 
1 peptide were used as negative controls.  A protein of approximately 15 kDa in 
size was pulled down from the M. tuberculosis whole cell lysate by phage1-
synpeptide irrespective of the stringency of the wash buffer (Figure 3.6).  
Moreover, this peptide was not detectable on the PAGE gel using Coomassie 
staining when phage1-synpeptide-Sc was used a capture peptide, indicating the 
specific nature of the interaction between the phage 1 displayed peptide and its 
mycobacteria binding partner (Figure 3. 6). 





Figure 3.5:  Sensograms showing the association of protease digested M. 
tuberculosis H37Rv whole cell lysatewith immobilized synthetic peptides using 
surface plasmon resonance Biacore™ 3000 
(A) Biotinylated phage1 synthetic peptide (phage1-synpeptide) and biotinylated 
phage 1 scrambled peptide (phage1-synpeptide-Sc) were captured with covalently 
bound streptavidin on a CM5 chip.  Protease-digested whole cell lysates of M. 
tuberculosis H37Rv with a total protein concentration of 100 µg/ml were injected 
over the immobilised peptides. (B) Control experiment using undigested M. 
tuberculosis H37Rv whole cell lysate.  Changes in surface plasmon resonance were 
monitored in real time and are shown in response units. 
 
                                   BiaCore Analysis: H37Rv lysate_2hr protease digestion





























BiaCore Analysis: H37Rv lysate_no protease

































Figure 3. 6:  SDS–PAGE of proteins pulled down from M. tuberculosis H37Rv 
whole cell lysate incubated with Streptavidin MagResyn™ magnetic beads and 
various peptides 
Coomassie stained 12% SDS–polyacrylamide electrophoresis gel of proteins 
obtained from pull down experiments.  Lane 1: molecular weight protein ladder. 
Lane 2: proteins pulled down from M. tuberculosis H37Rv whole cell lysate by the 
streptavidin beads in the absence of phage1-synpeptide.  Lanes 3: proteins pulled 
down from M. tuberculosis H37Rv whole cell lysate by the streptavidin beads that 
had been pre-incubated with 0.5mg of bio-phage1-synpeptide-Sc.  Lane 4: proteins 
pulled down from M. tuberculosis H37Rv whole cell lysate by the streptavidin 
beads that had been pre-incubated with 0.5 mg of bio-phage1-synpeptide.  The red 








Phage 1-synpeptide binding partner
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To identify the mycobacteria protein that associates with the phage 1 displayed 
peptide, we utilised mass-spectrometry as described in materials and methods 
section2.8.  The gel band corresponding to 15kDa on the PAGE gel was cut from 
each pull down fraction and analysed using mass-spectrometry.  Figure 3.6 A, 
describes the numbers of proteins identified from the corresponding band of each 
pull down fraction.  All proteins that were present in the beads only negative 
control were excluded as matrix non specific binders before any further analysis of 
the data (Figure 3. 6A).  Furthermore, before the final analysis of the data, proteins 
identified from the scrambled derivative pull down also were excluded as non 




This resulted in two groups of possible mycobacteria proteins that associate with 
peptide1-synpeptide protein.  Twenty eight were identified from the pull down 
using PBS as a wash buffer and 19 using the more stringent wash buffer of 0.5 M 
NaCl.  The two groups had five proteins in common (Figure 3. 6B) which are listed 
in Table 3.2.  Since these five proteins are common between the two experiments, 
they are the most likely candidates of the phage 1 displayed peptide target.  Three 
of the proteins are hypothetical proteins which have not been previously 
characterised.  Two of the proteins, identified as probable ribosomal proteins, have 
been characterised by experimentation or inferred by homology, to be associated 











Figure 3. 7:  A profile of proteins identified by mass spectrometry 
(A) Total predicted proteins before and after the subtraction of the nonspecific 
proteins from the bead matrix negative control and (B) Venn diagram illustrating 
the distinct and overlapping protein compositions of the phage1-synpeptide affinity 
















































































Phage1-synpeptide  (NaCl wash)
Phage1-synpeptide  (PBS wash)
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4.0   Discussion 
In this chapter, we used the traditional clone picking method and high-throughput 
sequencing to identify the highest enriched clones during biopanning.  Both HTP 
sequencing and random clone picking revealed multiple peptides that were enriched 
during the selection.  However, only HTP sequencing enabled quantitative 
measures of enrichment, which allowed us to compare and rank our multiple hits.  
Our results showed that only one phage clone, phage1, resulting from the 
biopanning of the CX7C library was significantly enriched during the selection.  
Interestingly, the traditional random clone picking method failed to identify this 
clone, despite the fact that HTP sequencing showed that this clone represented over 
80% of the sequenced population after the first three rounds of selection.  This 
result is in agreement with earlier findings showing that when comparing HTP 
sequencing to the traditional clone picking method, HTP sequencing accelerates the 
discovery of binders.  This result demonstrates the advantage offered by the higher 
Peptide 1 (NaCl wash) Peptide 1 (PBS wash)
Protein Name Localization Accession 
number
Unique peptides Coverage 
(percentage)













4 36 3 38.9
Hypothetical 








2 24.7 2 29.6
Hypothetical 
protein uncharacterised Q7D7S7_MYCTU 3 40.4 2 14.9
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resolution of the selection pools enabled by HTP sequencing, which will not be 
possible using random clone picking, since this method is limited by the number of 




When evaluating the binding of phage 1 to mycobacteria using an ELISA, there 
was no significant difference in the binding of this phage clone to the three 
mycobacterium speciestested.  This suggests that phage 1 binds to a surface 
molecule conserved across all mycobacteria species.  However, there are reagent 
similarities, like the plastic polystyrene microtiter wells, between the biopanning 
experiments and an ELISA.  It is possible that these similarities could contribute 
falsely to apparent binding as previously discussed by others.  This necessitates the 
use of a different method that does not include these materials, to further validate 
intended target binding.  Indeed, when the peptide displayed by phage 1 was 
evaluated on surface plasmon resonance technology, the results showed that this 
peptide is able to associate with the M. tuberculosis H37Rv whole cell lysate while 
its scrambled counterpart exhibited minimal binding.  The diminished binding of 
the scrambled peptide shows that the phage1-synthetic peptide sequence is 
important for its specific interaction with mycobacteria.  Furthermore, this peptide 
showed no binding to unrelated bacteria that were tested which is indicative of 




To further confirm target related enrichment of the phage 1 displayed peptide, the 
peptide sequence was searched on the SARUTUP web server which has a database 
for non target related peptide sequences resulting from phage display (Huang et al., 
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2010).  This peptide was not identified as a non target binding peptide.  However, a 
phage displaying the same peptide, CPLHARLPC, has recently been isolated and 
characterised as binding to the IV.C102 H1N1 monoclonal antibody and the swine-
origin influenza virus A sera (Zhong et al., 2011).  This monoclonal antibody has 
previously been demonstrated to bind to the type A H1N1 influenza strain epitopic 
peptide localised in residues 207-225 of the hemagglutinin HA1 subunit (Kiselar 
and Downard, 1999).  However, there is no sequence similarity between the 
IV.C102 monoclonal antibody epitope (AIYHTENAYVSVVSSHYNR) on the 
hemagglutinin protein and the peptide displayed by phage 1.  Luchesse and 
colleagues (2009) further characterised that peptide AIYHTENA is the minimal 
determinant epitopic region required for IV.C102 binding (Lucchese et al., 2009), 
which only has two amino acids in common, histidine and alanine, to the phage 1 
displayed peptide.  Nevertheless, the phage 1 displayed peptide contains five 
hydrophobic amino acids (out of nine), and the minimal epitopic peptide of the 
IV.C102 antibody also includes four hydrophobic amino acids (out of the eight).  
This may suggest that the interaction of this peptide with either the IV.C102 H1N1 





The surface of mycobacteria has multiple possible binding partners for the phage 1 
displayed peptide.  These potential ligands vary in their nature, ranging from cell 
wall proteins, glycans and free lipids (Brennan, 2003b).  In this work, we have 
demonstrated that the highly enriched phage 1 peptide binds to amycobacterial 
protein of approximately 15 kDa in size.  However, the identification of the target 
protein requires further validation.  Nonetheless, our mass spectrometry 
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experiments leads to five potential targets, of which three are hypothetical and have 
not been characterised to date.  However, there is limited literature on two of these 
potential targets, namely the probable ribosoml proteins S11 and L11 RplK.  These 





There isreported evidence of a large number of ribosomal proteins that are 
membrane associated in M. tuberculosis.  Sinha and colleagues (2004) reported 28 
ribosomal proteins that are membrane associated (Sinha et al., 2005), while in the 
preceding year Gu and colleagues (2003) also reported a number of membrane 
associated ribosomal proteins in M. tuberculosis (Gu et al., 2003).  The localisation 
of the S11 protein is inferred from homology to similar proteins.  While the 15 kDa 
L11 rplK protein (Festa et al., 2010) has been shown using 2DLC-MS/MS to be 
localised in the cell wall of M. tuberculosis (Mawuenyega et al., 2005).  The size of 
these proteins is in agreement with our SDS PAGE size estimate of the potential 
phage 1 peptide binding partner, while their localisation agrees with the 
hypothesised localisation of the mycobacteria partner based on the selection target, 
which was surface exposed target.  Taken together, these two proteins makes for 




In conclusion, these findings show that phage display combined with HTP 
sequencing identified a specific peptide that bind to a mycobacteria-associated 
ligand.  The peptide CPLHARLPC, which binds to a mycobacteria surface exposed 
protein, could be further developed as detection probe for TB infection.   
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EsxG is one of the secreted substrates of the ESX-3 secretion system found in 
mycobacteria.  ESX-3 has been hypothesised to be responsible for the secretion of 
some still unrecognized factor required for the optimal uptake of iron (Siegrist et 
al., 2009) and zinc (Serafini et al., 2009).  There  is evidence that M. tuberculosis 
experiences low iron conditions during macrophage infection (Gold et al., 2001)and 
that EsxG expression is repressed by the iron-dependent repressor (IdeR) when iron 
is available in both M. tuberculosis (Rodriguez et al., 2002) and M. smegmatis 
(Maciag et al., 2009).  Taken together, we reasoned that EsxG might possibly be 
expressed in the infected host and can be investigated as a potential tuberculosis 
biomarker if an appropriate probe such, as an aptamer, was available to detect the 
protein.  Aptamers are nucleic acid molecular probes, which have been explored as 
alternative recognition molecules to antibodies.  In addition, some aptamers are 
able to inhibit the function of their targets similar to inhibitory  antibodies (Bock et 
al., 1992, Hirao et al., 2000, Rhie et al., 2003, Tasset et al., 1997, Xu and Ellington, 
1996).  This chapter describes the isolation of 2'-fluoro-pyrimidine substituted 
RNA aptamers against the M. tuberculosis ESX-3 secreted protein, EsxG.  After 
five rounds of aptamer selection using surface plasmon resonance at least five RNA 
aptamers were selected from an initial combinatorial library with a diversity of 
1014.  Two high affinity monoclonal aptamers, GH 43 and GH 78, were found to 
preferentially bind EsxG over its homologous EsxA protein, which could be used 
for the development of novel diagnostics or techniques to investigate the role of 
EsxG in infection. 
 Chapter Four: Selection of RNA aptamers against EsxG 
 
95 
1.0   Introduction 
Iron is an essential element for many organisms in a variety of metabolic and 
regulatory pathways.  Since the innate immune system has evolved various 
mechanisms to restrict iron availability to microbial invaders, intracellular 
pathogens like M. tuberculosis developed countermeasures to obtain iron from their 
host (Ganz, 2009).  There is now evidence that indicates M. tuberculosis does in 





The mycobacteria siderophore mediated iron acquisition pathway is described in 
chapter 1 (section 1.4).  Of importance is that the ESX-3 secretion system,which is 
one of five type 7 secretion systems (T7S) identified in mycobacteria, has been 
shown to be essential for growth in low iron conditions (Serafini et al., 2009, 
Siegrist et al., 2009).  In brief, Siegrist and colleagues (2009) convincingly 
demonstrated that a M.smegmatis mutant which lacks ESX-3 (∆ESX-3) cannot be 
rescued by the exogenous addition of purified siderophore, mycobactin, indicating 
that the mutant is unable to use iron-bound mycobactin.  In addition, Serafini and 
colleagues (2009) used a M.tuberculosis conditional mutant to demonstrate that 
ESX-3 is responsible for the secretion of some unknown factor(s) which is required 




Until recently there was no high-throughput method to screen for possible T7S 
substrates, since the T7S had no known signal peptide for secretion.  Daleke and 
colleagues (2012) have only recently identified the YxxD/E motif as a signal 
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peptide for the T7S, which can now be used to identify a number of potential 
unknown T7S substrates (Daleke et al., 2012).  To date, there is evidence to show 
that the heterodimer EsxG:EsxH is secreted by ESX-3(Lightbody et al., 2004, 
Siegrist et al., 2009).  Since the ESX-3 system is critical in low iron environmentsit 
is probable that EsxG or EsxH are expressed in an infected host and can be 




Traditionally, antibodies are used as recognition probes for biomarker discovery. 
However antibodies have their limitations.  Their synthesis requires animals or cell 
culture and they are limited by definition to immunogenic targets.  In the recent 
past, aptamers have been investigated as alternative recognition molecules to 
antibodies.  They are simpler to produce by means of chemical synthesis and are 
not limited to immunogenic targets.  They have the ability to recognize, bind and in 
some cases inhibit function of their targets similar to that of antibodies (Bock et al., 
1992, Hirao et al., 2000, Rhie et al., 2003, Tasset et al., 1997, Xu and Ellington, 




This chapter describes the selection of RNA aptamers against EsxG using surface 
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2.0   Materials and Methods 
 
2.1   Expression of EsxG protein 
EsxG from M. tuberculosis H37Rv was cloned into the bacterial vector pET41A 
(gift of Professor Eric Rubin, Harvard Medical School, Boston, MA).  The vector 
was used to transform Escherichia coli BL21 (DE3) cells and recombinant clones 
were selected on Kanamycin (50 µg/ml).  Expression studies were performed as 
follows; a single colony was used to inoculate 5 ml LB media (containing 
Kanamycin 50 µg/m), followed by incubation at 37ºC overnight.  The pre-
inoculum (2 % (v/v) of the overnight culture) was then used to inoculate LB 
medium, the culture was incubated at 37 ºC until the OD600nm was between 0.5 and 
0.6.  The expression was induced by addition of IPTG to a final concentration of 
0.5mM, then incubation at 30ºC for 4 h.  The cells were harvested by 
centrifugation using the Sorvall RC-5B super speed centrifuge at 10000 RPM for 




2.2   Purification of EsxG protein 
The cell pellet was resuspended in 20mM Tris buffer [pH 7.5], containing 0.5M 
NaCl, and lysed using sonication for non denaturing purification.  The cells were 
also lysed using B-PER (in phosphate buffer, 50mM [pH 7.5]), bacterial protein 
extraction reagent (Thermo Fisher Scientific, Rockford, Illinois) for denaturing 
conditions.  Prior to purification the supernatant was ultracentrifuged using the 
Sorvall RC-5B super speed centrifuge at 20 000 RPM for 30 min at 4ºC.  The 
recombinant protein was purified using immobilized metal affinity chromatography 
(IMAC) packed with Protino® Ni-TED resin (Machery-Nagel, Düren, Germany).  
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Bound tagged EsxG was eluted with 250 mM imidazole in 20 mM phosphate buffer 
containing 0.5 M NaCl.  Eluted fractions were buffer exchanged to 20mM Tris 
buffer [pH 7.5] using  the Vivaspin™ sample concentrators (GE Healthcare 
Lifesciences, Buckinghamshire, United Kingdom) with a molecular weight cut off 
at 10 kD. This size exclusion method was also used to remove proteins that co-
purified with EsxG.  The BCA protein assay kit (Thermo Scientific, Illinois, U.S.A) 
was used to determine the concentration of the purified protein.  The purity of 
protein was assessed in a 18% Tris-tricine SDS/PAGE gel stained with Coomassie 
blue.  EsxG expression was confirmed using mass spectrometry.  Identification was 
on an algorithm Thorough search in Protein Pilot. An identification confidence of 




2.3   SDS/PAGE and Western blotting 
The 18% Tris-tricine SDS/PAGE gel was used as described in (Schagger and von 
Jagow, 1987).  Gel electrophoresis of samples was carried out at 200V for 2 hours. 
Gels comprised a stacking gel of 5% (w/v) acrylamide and a separating gel of 18% 
(w/v) acrylamide.  Proteins separated by SDS/PAGE were transferred to Hybond-P 
PVDF transfer membrane (GE Healthcare Lifesciences, Buckinghamshire, United 
Kingdom) with a Bio-Rad Transblot semi-dry transfer cell at 12V for 2 hrs.  To 
confirm the presence of the histidine tagged EsxG protein the protein bands were 
detected using a 1:10 000 dilution of the anti-histidine HRP-conjugated antibody 
(Qiagen, Hilden, Germany).  A pre-stained ladder was used for the Western blot 
and the detection was accomplished with a colorimetric HRP substrate, TMB 
(3,3′,5,5′-tetramethylbenzidine) (Thermo Fisher Scientific, Rockford, Illinois). 
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2.4   Mass spectrometry analysis, LC-MS/MS 




2.5   Preparation of the RNA library 
The DNA library contained 50 nucleotides of random sequences flanked by 44 and 
40 residues on the 5' and 3', respectively, giving a full sequence of 134 nucleotides, 
and was synthesized by Integrated DNA Technologies (Coralville, Iowa).  The 5'-
fixed region was 5’-AAT TAA CCC TCA CTA AAG GGA ACT GTT GTG AGT 
CTC ATG TCG AA-3'.  The 3' fixed region that contained the T7 promoter for in 
vitro transcription (underlined and bolded) was 5’-TAA TAC GAC TCA CTA 




2.6   Amplification of the DNA Library 
The DNA library was amplified by PCR under mutagenic conditions.  The reaction 
mix consisted of 170 pmol of the single stranded DNA library, 1.1 µM of the T3 
primer (T3SELEX5') and 3.3 µM of the T7 primer (T7SELEX3'), 150 µM of each 
dNTP, 10 mM of MgCl, and 5U of the GoTaq® DNA polymerase mix (Promega) 
in a 100µl final volume.  The PCR conditions were as follows; template denaturing 
was performed at 93ºC for 30 seconds, annealing was at 55ºC for 30 seconds and 
elongation at 72ºC for 1 min with the final extension at 72ºC for 8 min.  Cycles 
varied from 1 to 5, according to the maximum amount of amplicon obtained before 
amplification occurred.  The resulting PCR product was cleaned up using the 
Wizard® SV Gel and PCR clean-up system (Promega, Wisconsin, USA). 
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2.7   In vitro transcription 
The resulting dsDNA was converted to an RNA library using the T7 RNA 
polymerase.  In the transcription reaction mixture, CTP and UTP were replaced 
with2' fluoropyrimidine triphosphates, 2'-F-CTP and 2'-F-UTP (TriLink, USA) to 
produce ribonuclease resistant RNA.  For a 100 µl transcription, 225 pmol ofthe 
DNA template was used with 1.5 mM (final concentration) each of the 2' 
fluoropyrimidine triphosphates (TriLink, USA), 0.5 mM of unmodified purine 
nucleotides (Fermentas, USA), a transcription buffer (40 mM TrisCl [pH 7.9], 6 
mM MgCl2, 10mM DTT, 2 mM spermidine) and 200 units of T7 RNA polymerase 
(New England BioLabs, Massachusetts, USA) were used.  The reaction mixture 
was incubated at 37oC, overnight.  Subsequently, the template DNA was removed 
by DNase I digestion for one hour.  Free nucleotides were removed from the RNA 
transcript using a Sephadex-G50 column.  Proteins were removed from the RNA 
using phenol/chloroform extraction as described in (material and methods2.8) and 
the RNA was subsequently precipitated using ethanol as described in (material and 




2.8   Phenol/chloroform extraction of RNA 
An equal volume of Tris-buffered [pH 5] phenol/chloroform/isoamyl alcohol (v/v 
25:24:1) was added to the RNA followed by vigorous mixing using a vortex and 
centrifugation at 14 000 rpm for 5 min.  The aqueous (upper) phase containing 
RNA was transferred to a clean Eppendorf tube.  An equal volume of 
chloroform:isoamylalcohol (v/v) was added to remove any trace of phenol followed 
by vigorous mixing using a vortex and centrifugation at 14 000 rpm for 5 min.  The 
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RNA contained in the aqueous (upper) phase was transferred to a clean Eppendorf 




2.9   Ethanol precipitation of RNA 
The RNA was precipitated by addition of 0.1 vol. of 3 M sodium acetate [pH 5.2], 
and 2.5 vol. of absolute ethanol.  After 2 hours at -80oC, the RNA was pelleted by 
centrifugation at 14 000 rpm (4oC) for 30 min.  The pellet was washed once with 3 
vol. of 70% ethanol to remove residual salt, air-dried and resuspended in distilled 
water.  The transcribed RNA poolintegrity was visually assessed on a 7 M urea gel, 





2.10   In vitro selection of RNA aptamers against EsxG protein using the 
NTA system on the BIAcore™ 3000 
The SELEX process was performed using surface plasmon resonance on the 
BIAcore™ 3000 instrument.  The HBS-P (0.01 M HEPES [pH 7.4], 0.15 M NaCl, 
0.005% Surfactant P20) continuous flow buffer (GE Healthcare Lifesciences, Ohio, 
USA) was used in all the biacore experiments on the nitrilotriacetic acid (NTA) 
chips.  All samples which were injected onto the sensor chip were spun at 14 000 
rpm for 1 min to dislodge air-bubbles.  Briefly, the recombinant EsxG was 
immobilized on the NTA sensor chip (GE Healthcare Life Sciences, Ohio, USA) 
via nickel chelation.  The NTA chip was briefly washed with 20 µl of regeneration 
solution (HBS-P supplemented with 0.35M EDTA, adjusted to [pH 8.3]).  The 
surface of the NTA sensor chip wasfirst activated with Ni2+ ions using 30 µl of the 
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nickel solution (500 µM NiCl2 in HBS-P, 50 µM EDTA) at a flow rate of 20 
µl/min, to saturate the chip.  Following surface activation, 30 µl of 200 nM of EsxG 
(His6) was injected at 2 µl/min.  The transcribed RNA pool (representing 
approximately 1014 unique molecules) was denatured at 95ºC for 4 min and 
refolded at room temperature in HMCKN buffer (10 mM Hepes [pH 7.4], 1 mM 
MgCl2, 1 mM CaCl2, 2.7 mMKCl, 150 mM NaCl) for an additional 4 min.  The 
RNA pool was injected for 2 min into the flow cell at a flow rate of 20 µl/min.  
After each selection cycle the bound RNA was eluted from the NTA using 
theelution buffer (7 M urea, 5 mM EDTA).  The recovered RNA was then 
converted to cDNA by reverse transcription using the RevertAid M-MuLV Reverse 
Transcriptase (Fermentas, USA) according to manufacturer’s protocol.  The cDNA 
was amplified by PCR as described in (2.6) with the exception of the MgCl2 which 
was reduced to 1.5 mM.  The number of cycles was determined for each round of 
selection to avoidoveramplification.  
After five rounds of selection, the enriched RNA pool was reverse transcribed; the 
resulting cDNA amplified byPCR and cloned into the TA cloning vector using the 
pGemT-Easy cloning kit (Promega, Wisconsin, USA) as per manufactures 
instruction.  The pGemT-Easy ligation mix was transformed into DH5α chemically 
competent cells (Invitrogen, Carlsbad, CA, USA) as described in 2.11.  The 
individual clones were screened for insert and the insert sequence identified by 




2.11   Transformation of bacterial competent cells 
DH5α chemically competent cells (Invitrogen, Carlsbad, CA, USA) were thawed 
on ice, and 2 µl of the pGemT-Easy ligation reaction was directly added into 50 µl 
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competent cells and mixed gently.  The transformation mix was incubated on ice 
for 30 min., followed by heat shock for 30 seconds in the 42°C water bath and 
immediately placed back on ice. 250 µl of SOC medium (Invitrogen, Carlsbad, CA, 
USA) equilibrated at room temperature was added to the transformation mix, and 
the vial was shaken (225 RPM) at 37°C for at least 1 hour.  Different volumes (10-
50 µl) of transformed bacteria were plated on LB agar plates containing 50 µg/ml 




2.12   Colony PCR for validation of monoclonal aptamer clones 
The T3SELEX5' and T7SELEX3' primer pair (Appendix Table 1) was used for 
screening insert positive clones for colony PCR.  A single colony from the plated 
transformed bacteria was used for each PCR reaction.  The reaction mix consisted 
of 0.5 µM of the T3SELEX5 primerand 0.5 µM of the T7SELEX3' primer,80 µM 
of each dNTP, 1.5 mM of MgCl, and 1U of the GoTaq® DNA polymerase mix 
(Promega) in a 100 µl final volume.  The PCR conditions were as follows, template 
denaturing was performed at 95ºC for 10 min, annealing was at 55ºC for 30 seconds 
and elongation at 72ºC for 30 seconds with the final extension at 72ºC for 8 min.  
Twenty five cycles of PCR were performed.  The resulting PCR product was 
evaluated for the presence of a 150 bp insert which represented thepresence of the 
insert.  Insert positive clones were subsequently sequenced to obtain monoclonal 
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2.13   Binding assay using the nickel chelation on theBIAcore™ 
Screening of monoclonal RNA aptamers was performed using the modified NTA 
immobilization protocol as described in (Willard and Siderovski, 2006).  Briefly, 
the BIAcore™ 3000 biosensor instrument (GE Healthcare Lifesciences, Ohio, 
USA) flow rate was set at 5 µl/min.  Nickel was bound to the NTA chip using the 
nickel solution (500 µM NiCl2 in HBS-P, 50 µM EDTA).  The carboxymethylated 
dextran (CMD) surface was then activated using 70 µl of N-hydroxysuccinimide 
(NHS)/1-ethyl-3(3-dimethylaminopropyl)-carbodimide hydrochloride (EDC).  
EsxG (30 µl, 200nM) in pH 7.4 running buffer, was then captured at a low flow 
rate (2 µl/min).  This was followed by the blocking of the uncoupled amino reactive 
sites on the CMD surface by injecting 70 µl of 1 M ethanolamine-HCl[pH 8.5].  
Nickel and non-covalently coupled EsxG were subsequently stripped from the 




2.14   Binding assay using the amine coupling on the BIAcore™ 
A standard amine coupling protocol was followed according to manufactures 
instructions (Biacore, GE Healthcare Lifesciences, Ohio, USA).  The BIAcore™ 
3000 biosensor instrument (GE Healthcare Lifesciences, Ohio, USA) flow rate was 
set at 10 µl/min and the carboxymethyl groups on the chip were activated by 
injecting 50 µl of 0.5 M N-hydroxysuccinimide (NHS), and 0.2 M N-ethyl-N'-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC).  The EsxG protein was 
diluted into 10 mM sodium acetate, pH 4.5 to a final concentration of 2 µM and 
was injected onto the activated surface, resulting in amine coupling of the protein to 
the activated surface.  The remaining activated carboxymethyl groups were blocked 
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by injecting 70 µl of 1 M ethanolamine-HCl, pH 8.0, which also helped elute non-




2.15  Binding kinetics analysis using the amine coupling on the BIAcore™ 
Affinity measurements were performed at room temperature (25oC), which was the 
same temperature used during selection.  1000–1200 RU of EsxG was covalently 
immobilized on the chip as described in (material and methods 2.14).  The 
concentration of the monoclonal RNA aptamer was measured using the nanodrop, 
and dilution series of the aptamer was prepared (5 nM– 500 nM).  Each 
concentration of the aptamer (20 µl, starting with the lowest) was injected at 10 
µl/min and allowed to dissociate over 600 seconds.  To ensure that there was no 
residual RNA left on the surface before the next concentration injection, the ligand 
was regenerated by injecting 10 µl of freshly prepared 100 mM NaOH to remove 
the RNA that was still bound.  Data was analysed using the BIAevaluation 3.0 
(Biacore, GE Healthcare UK Ltd, Buckinghamshire, England) and GraphPad Prism 
5.0 (GraphPad software Inc., USA) software and the affinity constant was 




2.16  Iron Starvation Experiments 
The iron starvation experiments were performed by Marte Singsås Dragset at 
Harvard University.  The strains and methods used for these experiments have been 
previouly described (Siegrist et al., 2009).  Briefly, M. smegmatis was cultured in 
7H9 medium 0.05% Tween-80 and 10% albumin-dextrose-catalase (ADC) in the 
presence of kanamycin and hygromycin as needed.  The culture was then 
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subcultured once in chelated Sauton’s medium (consisting of 60 ml of glycerol, 0.5 
g of KH2PO4, 2.2 g of citric acid monohydrate, 4 g of asparagine, and 0.5% 
Tween-80).  After adjustment of the pH to 7.4, the medium was stirred 1–2 days at 
room temperature with 10 g of Chelex 100 resin (Sigma).  The medium was 
filtered, and 1 g of MgSO4•7H2O was added as asterile solution), and then diluted 
1:1,000 in chelated Sauton’s medium without antibiotics containing either aptamer 
or HMCK aptamer refolding buffer.  The growth curves for the cultures was 




3.0   Results 
 
3.1   Purification of EsxG protein 
His-tagged EsxG was expressed in soluble form in E. coli cells and subsequently 
purified using IMAC.  The concentration of the purified protein was about 300 
µg/ml and the total yield was 0.6 mg per litre of culture as quantified by the BCA 
assay.  Disruption of the E.coli pellet was performed under native conditions using 
sonication as well as denaturing conditions using the B-PER reagent (Pierce Protein 
Research Products, Rockford, Illinois) which contained detergent.  The purification 
procedure involved a single pass over the Ni-TED column, resulting in the capture 
of most of the expressed EsxG by the column as indicated by the very faint band 
corresponding to EsxG in the lane showing the flow through (Figure 4. 1A). 
However, several contaminating bands were consistently observed along with the 
eluted EsxG protein (Figure 4. 1A).  Co-purified protein bands were removed by 
size exclusion.  Using this approach we were able to purify pure fractions of the 
expressed protein. 
 Chapter Four: Selection of RNA aptamers against EsxG 
 
107 
The molecular mass of the purified EsxG was estimated at 11 kDa when compared 
to the protein standards (Biorad, CA, USA) on 12% SDS-PAGE gel (Figure 4. 1B).  
A similar band migration pattern was observed whether the protein was purified 
under native or denaturing conditions using the B-PER reagent (Pierce Protein 
Research Products, Rockford, Illinois).  The presence of EsxG protein was 
validated by Western blot using the horseradish peroxidase conjugated anti-




In addition, mass spectrometry-based peptide sequencing was used to confirm 
protein identity.  The results from the gel digestion of the protein bands and an in 
solution digest of the purified fraction identified EsxG (His6) with 100% and 89.3% 
sequence coverage, respectively.  Taken together, these results indicate that EsxG 
was successfully purified using nickel chromatography together with size 













Figure 4. 1:  Purification and SDS-PAGE analysis of purified EsxG protein 
EsxG was purified on a Ni-TED column. (A)Samples from various steps of the 
purification procedure were analyzed by 12% SDS-PAGE gel, and the bands were 
visualized by Coomassie protein staining. Lane 1 showing the lysed pellet after 
sonication; lane 2 showing the flow through material from Ni-TED columns; lane 3 
shows the protein eluted with 50 mM imidazole (B) Coomassie stained 12% SDS-
PAGE gel of purified EsxG after size exclusion purification. (C) Western-blot of 
EsxG using the horseradish peroxidase conjugated anti-histidineantibody. A 
prestained ladder was used for the Western blot and the detection was 
accomplished with a colorimetric substrate, TMB.  
 
 
3.2   Amplification and transcription of the DNA library 
The first step in the SELEX experiments was to use a pool of variant sequences 
from which RNA ligands of relatively high affinity for EsxG could be selected.  For 
this experiment we chose a similar DNA library previously used by Khatiand 
colleagues (2003) to isolate high affinity aptamers against the surface glycoprotein 
of HIVgp120.  
B CA
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A 134-mer DNA template randomized at 50 nucleotide positions (Figure 4. 2A) 
was amplified by mutagenic PCR with varying number of cycles to achieve 
sufficient template without over amplification of the PCR product (Figure 4. 2B). 
Four PCR cycles resulted in the cleanest single band of the expected size to be used 
for transcription (Figure 4. 2B).  Fewer cycles did not yield enough template, while, 
additional cycles resulted in over amplification of the PCR product as indicated by 




The resulting dsDNA template was purified using the membrane based system, 
Wizard® SV Gel and PCR Clean-Up System kit (Promega, Wisconsin, USA) and 
transcribed in vitro using 2'-fluoro-pyrimidines as described in (2.7).  The 
transcription product was digested using DNase I to remove the template DNA. 
Free nucleotides were removed from the resulting RNA using a Sephadex-G50 
column prior to the removal of proteins using phenol/chloroform.  Subsequently, 
the RNA was precipitated using ethanol and the quality confirmed on a denaturing 
urea gel (Figure 4. 2C). 






Figure 4. 2:  PCR amplification and transcription of the variant template 
(A) The double–stranded DNA template was transcribed in vitro using the T7 RNA 
polymerase to give a 117 nucleotide 2'F–RNA molecule.  (B) Agarose gel analysis 
of the PCR products, using the T3SELEX5' and T7SELEX3' primer pair, yielded 
by varying numbers of cycles, showing the cleanest band of interest produced after 
4 cycles.  (C) Urea gel analysis of the RNA transcription, showing the RNA 
transcript before and after DNaseI digestion and the cleanest RNA transcript after 
desalting using a Sephadex-G50 column and ethanol precipitation. 
 
3.3   Selection of RNA aptamers using the BIAcore™ 
For this selection the target protein was immobilized on the NTA chip (Figure 4. 
3A) as described in (2.13).  We reasoned that the NTA system will be more suitable 
than the CM5 chip because it allowed for a similar orientation of the recombinant 
A
B
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protein for every round of selection, standardizing the SELEX surface.  This 
advantage in orientation is achieved because the NTA system will immobilise the 
protein ligand via the histidine tag, meaning all proteins on the surface of the sensor 
chip will be in the same orientation.  In contrast, coupling on the CM5 chip results 
in a random orientation of the protein on the sensor chip surface because the active 
succinamide esters on the sensor surface will form covalent bonds with the reactive 




During the first selection cycle, approximately 1014 RNA sequences (20 µg) were 
injected into the flow cell for binding to the recombinant EsxG as described in 
(2.10).  The bound RNA was eluted off the immobilized EsxG using7M urea buffer 
to provide one fraction (4µl) of RNA.  The eluted RNA was used as a template to 
regenerate the binding RNA species via reverse transcription, PCR, and in vitro 




During the subsequent rounds of selection, the amount of starting RNA for each 
round was decreased to 10 µg.  This was done to reduce the competition among 
sequences for binding to the limited amount of EsxG on the chip surface, while 




Prior to the final round of selection, round five, the RNA was pre-cleared by 
passing it over a nickel charged flow cell before selection on EsxG.  This was done 
to reduce the selection of aptamers that might bind to the chip matrix.  After five 
rounds of selection the amount of target bound species increased when compared to 
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the unselected library, as indicated by the increase in response units of the selected 
biacore selection (Figure 4. 3B).  This indicated that the anti-EsxG aptamers were 
enriched in the round 5 polyclonal pool of RNA.  
 
Figure 4. 3:  Isolation of aptamers that bind to EsxG 
(A) Nickel was bound to an NTA sensorchip by the injection of nickel solution 
(500µM NiCl2 in HBS-P, 50µM EDTA).  EsxG (200 nM) in eluent buffer was 
captured on the biosensor surface by injection at a low flow rate (30 µl, 2µl/min) 
before binding of polyclonal RNA pools.  (B) After five rounds of selection, the 
polyclonal pool of 2’F-RNA was analysed for binding to covalently bound EsxG on 
a CM5 chip.  The binding of the final round of selection was compared to the initial 
library before selection.  The binding curve was derived after subtraction of 
measurements from the RNA buffer only control. 
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3.4   Cloning and sequencing of monoclonal aptamers 
After five rounds of selection the resulting PCR product was cloned into pGEM-T 
Easy vector using TA cloning.  Mutagenic PCR which was used during selection 
was abandoned by reducing the concentration of MgCl2from 7.5 mM to 1.5 mM 
during cloning and subsequent screening procedures.  This allowed for the high 
fidelity amplification of the template and hence conserved the nucleotide sequence 
of the EsxG-binding species.  The TA cloned aptamers were used for bacterial 
transformation as described (2.11) and colony PCR, using the T3SELEX5' and 
T7SELEX3' primer pair (Appendix Table 1) was performed to screen bacterial 
transformants for inserts.  Figure 4. 4 shows a representative agarose gel of colony 
PCR products used to evaluate the presence of the monoclonal aptamer insert.  A 




All the 79 insert clones were sequenced of which sequencing was successful for 57 
of the clones.  Aptamer clones were arbitrarily numbered, with the prefix G, 
denoting the EsxG target protein.  Of the 57 successful sequences, three clones 
(G23, G49 and G68) had a random region of less than 50 nucleotides, while one 
clone (G26) had three additional nucleotides inserted in the random region resulting 
in the random region of 53 bases.  Five clones had identical sequences (G31 and 
G34; G36 and G71; G43 and G94; G70 and G76; G78 and G98), and the rest had 










Figure 4. 4:  PCR screening for insert positive clones 
Agarose gel (2%) representing the PCR screening for insert–positive clones that 
contain monoclonal aptamers.  Positive clones (+) are indicated by the presence of 
the expected150 base pair double stranded DNA.  The clones without insert are 
presented by the minus sign (-). One hundred clones were screened, of which 79 




























Figure 4. 5:  Sequences of the monoclonal aptamers from the final round of selection. 
Monoclonal aptamerswere randomly sequenced from the final round of selection.  The sequences that were represented more than once are 
indicated by a red arrow, while the sequences that showed binding higher than the control during screening on the NTA system are indicated 
by a  black arrow.G43 which was present in both groups is indicated by dotted arrow 
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3.5   Screening of monoclonal aptamers binding to the EsxG 
Individual aptamer clones were screened against recombinant EsxG.  The initial 
screening of the monoclonal aptamers was performed on the NTA chip to maintain 
a similar orientation of the recombinant protein to that usedduring SELEX. 
However, the intrinsic deficiency of the NTA system is the slow and continuous 
dissociation of the immobilized protein.  To overcome this limitation a modified 
protocol for the immobilization of protein on NTA sensor chips using His6 tag 
capture followed by free amine coupling was used as described by Willard and 




Only four of the screened individual aptamer clones, namely G2, G4, G43 and G45, 
had a resonance signal higher than the buffer control after subtraction of the 
immobilization matrix flow cell without prior EsxG mobilization (Figure 4. 6B).  
Of these aptamers, G43 was identified twice during sequencing.  However, the 
response units obtained using this screening method was generally low, with 




Our rational was, therefore, to repeat the screening using amine coupling chemistry 
on the CM5 chip which results in a more stable immobilization of the protein on the 
biosensor surface.  However, the CM5 is limited in the number of regenerations 
that can be performed.  For this reason, we tested only clones that were identified 
more than once during sequencing as well as the three additional clones that gave a 
resonance signal higher than the buffer control during screening on the NTA chip. 
Interestingly, the results indicated that four of the five pairs that occurred more than 
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once during sequencing bind EsxG when amine coupled to the CM5 chip (Figure 4. 
7A-E).  However, out of the four clones that showed a binding response higher than 
that of the buffer control during NTA screening; only G43 which was also 
duplicated during sequencing, bound EsxG when amine coupled to the sensor chip 














Figure 4. 6:  Screening of the isolated clones on the NTA system 
(A) Nickel was bound to an NTA sensorchip by the injection of nickel solution 
(500µM NiCl2 in HBS-P, 50µM EDTA). EsxG (200 nM) in running buffer was 
captured on the biosensor surface by injection at a low flow rate (30 µl, 2µl/min) 
before binding of monoclonal RNA (B) After five rounds of selection, the 
monoclonal 2’F-RNAs were analysed for binding to covalently bound EsxGon a 
NTA chip.  The clones that were presented more than twice on sequencing are 
labelled grey, while the buffer control is labelled white.  The response units 
corresponding to the binding signal were derived after subtraction of measurements 
from the control flow cell. 
A
B











































































































































































































Figure 4. 7:  Screening for binding of selected aptamers on the CM5 chip 
Surface plasmon resonance sensorgram for EsxG interactions with (A-E) representative aptamers of the pairs that were duplicated during 
sequencing and (E-H) aptamers that showed abinding response higher than that of the buffer control during NTA screening.  The thick black 
lines represent the aptamer binding to EsxG, and the dotted lines the buffer control.  
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3.6   Characterisation of aptamers to EsxG 
Two aptamers, G43 and G78, with the highest response units during screening 




3.6.1  G42 and G78 secondary structure prediction 
With stranded RNA aptamers, intermolecular base pairing between complimentary 
base pairs results in the secondary structure of RNA.  Depending on the 
environmental conditions, a given RNA sequence may exist in multiple structures 
in solution.  We used the mfold web server (Zuker, 2003) to predict the minimum 
free energy (MFE) structures for each of the selected aptamers.  Aptamer G43 was 
predicted to have a single MFE structure (Figure 4. 8A) with a Gibbs free energy of 
-27.07 kcal/mol.  In contrast, aptamer G78 was predicted to have nine MFE 
structures (Appendix figure 2-A-H) with the lowest energy difference of 
9.44kcal/mol.  Since the energy difference between these structures is small, it is 




The structures with the lowest MFEfor each selected aptamer are shown in Figure 
4. 8A-B.  There were no apparentsimilarities between the MFE structures of 
aptamer G43 and aptamerG78, as predicted by mfold.  
 
 





Figure 4. 8:  Structures of anti-EsxG aptamers G43 and G78 
The structures and free energies of aptamer (A) G43 (B) G78 were predicted by mfold. Fixed primer sequences corresponding to the T3SELEX5' and T7SELEX3' primer 
regions are marked by red and navy dotted line, respectively. 
-27.07 kca/mol -28.20 kca/mol
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3.6.2  Binding kinetics of aptamers to EsxG 
Binding kinetics to EsxG of the two selected aptamers was determined using SPR.  
EsxG was immobilized on the CM5 biacore chip using amine coupling as described 
in section 2.14.  The concentration of the aptamer was measured using the 
NanoDrop spectrophotometer, and a dilution series (5nM – 500 nM) was prepared 
in HMCKN refolding buffer.  Each concentration of the analyte was injected at 
10µl/min and allowed to dissociate over 600 seconds.  The affinity constant was 
calculated based on a Langmuir one on one curve fit using the BIAevalaution 3.0.  
Representative curves of the kinetic analysis obtained from the biacore are shown 
in Figure 4. 9A-B.  The chi2values for all the kineticanalysis were between 4.2 and 
9.8.  Typically the chi2 less than 10 is indicative of good fitting to the model used, 
since our chi2 values are less than 10 this means that the Langmuirone model used 
for our aptamer kinetics study adequately describes our data.  The dissociation 
constants of the G43 and G78 aptamers were found to be about 8.04 ±1.90 and 
78.85 ± 9.40 nM, respectively. Overall, aptamer G43 bound EsxG with about 7 




3.6.3 Binding specificity of aptamers to EsxG 
To determine if the aptamers G43 and G78 are able to discriminate their binding to 
EsxG from its closely related protein, EsxA, I characterized binding using the 
biacore.  The ligand, EsxG or EsxA was immobilized in a similar manner as during 
kinetics studies as described in (2.14) and 500 nM of each aptamer was injected 
over the immobilized EsxG.  A two-tailed, unpaired t-test was used to analyse 
significance in the difference between binding of the aptamers to EsxG and EsxA.  
Response units measurements taken 100 seconds after aptamer injection has ended, 
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showed that both aptamers had significantly higher response units G43 (p < 0.05), 
G78 (p < 0.01) when binding to 2 µM of immobilized EsxG as compared to their 




Figure 4. 9:  Binding kinetics and specificity of EsxGaptamers G43 and G78 
Equilibrium kinetics of RNA aptamers (A) G43 and (B) G78 binding to 
immobilized EsxG using the BIAcore™3000.  Binding kinetic parameters were 
obtained using various concentrations of aptamer between (0-500 nM).  The 
graphsare a representative and standard deviations were calculated from three 
experiments.  (C) RNA-aptamers discriminate amongst closely related proteins, 
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injection of 500 nM G43 and G78 binding to immobilized EsxG.  A two-tailed, 
unpaired t-test was used to analyse significance (**p<0.01, *p<0.05). 
 
 
3.6.4  G43 and G78 does not retard mycobacteria growth under low iron 
conditions 
Certain aptamers are known to inhibit function of their target proteins.  To exploit 
this aptamer feature, we used the EsxG aptamers G43 and G78 to investigate 
whether interfering with EsxG would interfere with the optimal uptake of iron. 
Siegrist and colleagues (2009) have previously shown that the M. smegmatis fxbA- 
mutant (which has an insertion in the formyltransferase required for exochelin 
synthesis) shows a marked growth defect under conditions of iron starvation.  They 
further demonstrated that the double mutant strain fxbA-∆ESX-3 fails to grow in 




In order to test whether EsxG contributed to optimal uptake of iron, we added 100 
nM and 500 nM of the selected aptamers to a M. smegmatis fxbA- culture growing 
in low iron medium and compared it to wild-type.  We hypothesised that, if the 
aptamers inhibit function of EsxG and EsxG is indeed a soluble factor that is 
secreted by the ESX-3 secretion sytem for optimal iron uptake, the addition of the 
aptamers to the fxbA- mutant will have an additive increase in the growth inhibition 




Our results were in agreement to the previous findings published by Siegrist and 
colleagues (2009).  That is, the fxbA- mutants shows a marked growth defect, while 
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the fxbA- ∆ESX-3 mutant fails to grow in low iron culture medium.  However, the 
addition of aptamers G43 or G78 to fxbA- mutant culture did not show an additive 
growth reduction under low iron conditions (Figure 4. 10A-B).  The initial growth 
delay observed from the cultures with the aptamers is most likely an effect of the 
aptamer refolding buffer (HMCKN) as a similar trend is observed from the fxbA-
HMCKN control in the absence of the aptamer.  Similar experiments using aptamer 













Figure 4. 10:  Effect of G43 and G78 on mycobacterialgrowth under low iron 
conditions. 
The growth of wild-type (WT),exochelininsertional biosynthesis mutant (fxbA-), 
∆ESX-3 mutant, a double mutant (fxbA-∆ESX-3) and RNA refolding buffer control 
(fxbA- HMCK) in low iron Sauton’s medium. The aptamer experimental growth 
curves were performed on the fxbA-background with aptamer G43(A) G78 (B) 
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4.0   Discussion 
 
Antibody based diagnostic methods are still considered the standard in clinical 
diagnostics.  However, aptamers have been explored as alternative recognition 
molecules for diagnostics as in the case for the detection of thrombin  in thrombin 
related diseases in human blood (Centi et al., 2007, Heyduk and Heyduk, 2005, 
Xiao et al., 2005).  One of their main advantages is in their ease of synthesis that 
does not require animals or cell lines, making them cheaper to produce when 




In this study, we performed asurface plasmon resonance based SELEX, to select 
RNA aptamers that bind to the ESX-3 secreted protein, EsxG.  Our data shows that 
after five rounds of selection, we selected at least four RNA sequences that bind to 
EsxG (Figure 4.7).  This result is similar to that of an earlier study that identified 
RNA aptamers against the gp120 protein of HIV from the same random library 
after only five rounds of selection on the biacore (Khati et al., 2003).  Two of the 
aptamers selected in this study, G43 and G78, were analysed for equilibrium 
kinetics and the KD was found to be in the nanomolar concentration range.  




M. tuberculosis has five homologous T7S system (Gey Van Pittius et al., 2001, 
Tekaia et al., 1999).  ESX-1 is the most studied of these systems and is implicated 
in virulence of M. tuberculosis (Lewis et al., 2003, Pym et al., 2002).  The ESX-1 
secretion system secretes the EsxA:EsxB heterodimer which is homologous to the 
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EsxG:EsxH dimer which is secreted by the ESX-3 system.  To investigate whether 
the selected aptamers can discriminate amongst closely related proteins, we 
evaluated the binding of these aptamers to EsxA.  Our data showed that both 
aptamers bind to EsxG significantly more than to its homologue EsxA.  Taken 
together, this data demonstrate that aptamers G43 and G78 bind their target with 
affinities in the lower nanomolar concentration ranges and will likely show minimal 
cross reactivity with other homologous proteins secreted by other M. tuberculosis 
T7S system.  Thus these will make suitable recognition probes to investigate 




It is known that aptamers can bind proteins and in some cases inhibit function.  For 
example, aptamers that bind to haemagglutinin on the influenza virus also inhibit 
haemagglutinin-mediated membrane fusion (Gopinath et al., 2006) and the 
aptamers raised against the HIV gp120 protein inhibit HIV entry (Khati et al., 
2003).  However, the functions of EsxG or EsxG:EsxH are unknown, as a result 
there is no functional assay to ascertain whether the selected aptamer inhibit their 
function.  However as an initial screen to determine if the selected aptamers 
interfere with protein function we used an indirect system to determine if the 
aptamers bind to EsxG of M. smegmatis and interfere with the ESX-3 function of 
this organism.  The fxbA- mutant (which has an insertion in the formyltransferase 
required for exochelin synthesis) of M.smegmatis was used as a background strain 
for these experiments, since it shows a marked growth defect under low iron 
conditions (Siegrist et al., 2009).  Furthermore, a M. smegmatis fxbA-mutant, that 
also lacks ESX-3 (fxbA-∆ESX-3) fails to grow in low iron medium.  We evaluated 
the effect caused by the addition of the selected aptamers on the growth of the fxbA- 
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mutant in low iron medium.  Our findings show that both aptamer G43 and G78 
had no additive growth defect on the fxbA- mutant.  This was a preliminary 
experiment to illustrate how aptamers might be used to probe the function of 
specific M. tuberculosis proteins or systems.  It may have given a negative result 
because the aptamers were selected against the M.tuberculosis EsxG which is about 
72% similar to that of M. smegmatis.  Alternatively the aptamers may bind to EsxG 
without loss of function or finally that EsxG is not required for iron uptake. 




In conclusion, using surface plasmon resonance based SELEX, we have isolated 
strongly binding RNA aptamers after only five rounds of selection.  Our results also 
indicate that the selected RNA aptamers are able to distinguish between closely 
related proteins of M. tuberculosis namely, EsxA and EsxG.  The availability of 
these aptamers allows for possibly investigating whether EsxG can be used as a 
biomarker for tuberculosis diagnostics. I n the case where a functional assay is 
available to elucidate a function of protein, the ability of the aptamers to 
discriminate amongst homologous proteins can be exploited to elucidate the 
function of closely related proteins in mycobacteria.  
 
 



































 General discussion and conclusion 
 
131 
SUMMARY OF FINDINGS 
 
The primary aim of this study was to develop reagents that can detect M. 
tuberculosis with a view toward exploiting them as alternative molecular probes in 
the development of TB diagnostic tests.  I used two approaches: the selection of 
phage displayed peptides against the cell surface associated targets of mycobacteria 





Using two libraries of phage display technology (X12 and CX7C) and choosing 
random clones, I identified nine distinct phage displayed peptides that bind to M. 
tuberculosis with varying binding intensities.  Although choosing random clones is 
traditionally used to identify peptides enriched during biopanning, I found that the 
most enriched phage clone (phage 1, displaying CPLHARLPC peptide) that 
resulted from the panning of CX7C library was not identified using this method.  
Instead this peptide was only discovered using HTP Illumina sequencing, which 
revealed that after three rounds of selection more than 80% of the enriched 
population, was made up of phages displaying the CPLHARLPC peptide.  
However, this observation is limited by the small sample number, ten phage clones, 
used during random selection.  It is possible, that if a bigger sample size was 
selected when choosing random clones, this clone might have been found.  
However, to my knowledge there is no study that has investigated the minimum 
sample size for evaluating enrichment using phage display technology.  In fact, 
considering the phage display library sizes, which are in the order of 109, the 
variability of the targets and selection conditions used during biopanning, HTP 
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sequencing is becoming a more appropriate method for evaluating enrichment 




During further characterisation, the phage clone displaying peptide CPLHARLPC 
was shown to have on average a 2.5 fold increase in binding to M. tuberculosis 
when compared to the phage library before selection.  However, this phage clone 
also binds other species of mycobacteria, namely M. smegmatis and BCG (Figure 
3.3).  This observation was similar for all phages selected during this study (Figure 
3.1).  This is likely due to the similiar component structures that make up the 
mycobacteria cell wall and are conserved across species.  However, there are 
components on the surface of M. tuberculosis envelope that confer species 
specificity, like the mycolic acids (Shui et al., 2012) and some families of lipids 
such as phthiocerol diesters and phenolic glycolipids (Daffe and Draper, 1998, 
Rastogi and N, 1991).  However, it is likely that the experimental conditions used 
during biopanning for this study did not favour the selection of phage clones that 
bind to these components.  Although the enriched peptide indiscriminately binds 
intact mycobacteria and whole cell lysates (WCL), I found that it does not bind to 
lysates from other bacterial species (Figure 3.4).  Using an SPR binding assay, I 
showed that the association of the synthesised CPLHARLPC peptide to the M. 
tuberculosis WCL is abrogated after protease digestion, indicating that the M. 
tuberculosis target for phage 1 binding is likely to be a protein (Figure 3.5).  This 
data was collaborated by a pull-down assay which indicated that this phage binds a 
M. tuberculosis protein of approximately 15 kDa (Figure 3.6).  Using mass 
spectrometry we further identified five potential M. tuberculosis proteins as 
possible targets for phage 1.  These are listed in table 3.2.  While three of these 
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proteins are hypothetical proteins and there is no literature available for their 
localisation, one of the proteins, probable ribosomal protein S11, is hypothesised by 
homology to be membrane associated, while the other, probable ribosomal protein 
L11 rplK, has been experimentally validated to be membrane associated 
(Mawuenyega et al., 2005).  If these are truly ribosome-associated proteins, 
however, they would likely be found on the inner aspect of the cell membrane and 
would not be accessible to endogenous peptides.  Other proteins on this list have 
been found to be associated with the cell wall but their topology is unknown. 




Using SELEX and SPR technology, I isolated five nucleic acid aptamers that bind 
EsxG, a protein secreted by the ESX-3 secretion system of M. tuberculosis 
(Lightbody et al., 2004, Siegrist et al., 2009).  Two of the aptamers, GH 43 and GH 
78, were further evaluated for binding and showed binding affinity constants (KD) 
in the lower nanomolar ranges, 8.04 ± 1.90 nM and 78.85 ± 9.4 nM respectively.  
Furthermore, since aptamers are known to inhibit function of their ligands 
(Gopinath et al., 2006), we tested whether EsxG aptamerswould inhibit the function 
of EsxG to investigate whether EsxG is the ESX-3 secreted substrate that confers 
the growth defect associated with the ∆ESX-3 mutant under low iron conditions.  
However, the absence of the growth defect when these aptamers were added 
indicates that either EsxG alone is not responsible for this phenotype or that while 
these aptamers bind EsxG they do not affect its function associated with M. 
tuberculosis iron acquisition.  Further experiments that exploit these aptamers will 
be required to differentiate between these hypotheses. 
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IMPLICATIONS, FUTURE DIRECTION OF THE SUDY AND 
CONCLUSION 
 
Continuous improvements have been achieved in the development of TB diagnosis 
tests.  Indeed, new, automated and more sensitive tests like the GeneXpert that can 
also detect drug resistance TB are now in use (Evans, 2011, Vadwai et al., 2011, 
Van Rie et al., 2010, van Zyl-Smit et al., 2011).  However, despite these 
improvements, simple and inexpensive POC tests are still unavailable.  One of the 
challenges that hinder the rapid development of TB tests is that currently there is no 
biomarker, host or pathogen associated, that offers 100% specificity and sensitivity 
for diagnosing TB.  An ideal marker should also be able to differentiate between 
active and latent TB infection.  Moreover, discovery of biomarkers is only the first 
stage in the development of a diagnostic test.  This is usually followed by extended 
periods of research to develop the technology or detection reagents to use as a 




The approach adopted in this study demonstrates a shorter path to the development 
of a TB test.  I found that specific reagents that target the cell envelope can be 
developed using phage display technology.  The reagents I identified had genus- 
but not species-level specificity.  Other biopanning conditions might favour 
selection of species-specific phage displayed peptides.  These could include 
panning experiments targeting M. tuberculosis cultures grown in the absence of 
detergent and agitation, two in vitro manipulations that do not exist in clinical 
samples.  While the selected phage population from this study showed similar 
binding of the phage pool to M. tuberculosis grown under both conditions, the 
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enhanced binding to BCG and M. smegmatis indicates species-differences in 
abundance of the target under these culturing conditions.  These differences can be 
exploited by performing biopanning on cultured mycobacteria grown under 
different conditions.  This approach can potentially identify a group of phage-
display probes that can be used together to develop a more specific diagnostic test 
for TB.  In addition, while western blot assays to validate the biotinylated 
CPLHARLPC peptide were unsuccessful, other techniques, such as 2-D gel 
electrophoresis to further separate and differentiate proteins of similar molecular 
weight combined with protein identification using mass spectrometry might prove 
more successful.  Furthermore, evaluation of the selected probes on clinical 




Previously, the low abundance of these Esx proteins in culture caused a concern in 
their application in diagnostics.  However, whilst I was doing my work results were 
obtained for EsxA, which is homologous to EsxG, which demonstrated the protein 
isa potential candidate in the diagnosis of TB.  Rotherham and colleagues in our lab 
showed that DNA aptamers raised against the homologous ESXA protein are able 
to detect infection in sputum samples with a sensitivity of 100% and a specificity of 
68.75% (Rotherham et al., 2012).  Furthermore, in the preceding year, Hong and 
colleagues (2011) also demonstrated the presence of the same antigen, EsxA, in 
urine samples (Hong et al., 2011).  Taken together, this indicates that, in spite of the 
low abundance of these proteins in culture, they can be detected in clinical samples 
from patients.  However, further clinical studies on patients samples are required to 
validate the potential application of these reagents in TB diagnostics.   
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Long term, these reagents can be developed into molecular probes that can be used 
in clinical diagnostics.  Phage displayed peptides can be used either as intact phage 
or as peptides coupled to other support material like nanoparticles.  Numerous 
aptamer-based POC technologies that use platforms like biosensors (Navani and Li, 
2006), gold nano particles (Liu and Lu, 2006), and lateral flow device (similar to 
home pregnancy testing) (Liu et al., 2006) could make use of detection reagents to 
enable the development of a TB diagnostic test that meats the ASSURED criteria.  
Thus, this approach offers a clear path from discovering detection reagents to a 
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pUC/M13 forward primer 5´-CGCCAGGGTTTTCCCAGTCACGAC-3´





































Low pH/elution fraction 1
TBST wash/elution fraction 2








































Appendix figure 2: The structures and free energies of aptamer G 78 as predicted by mfold.(continued) 
-18.76 kcal/mol -27.10 kcal/mol
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Appendix Figure 3:  G43 and G78 do not inhibit growth under low iron 
conditions. 
Growth of (A-B) wild-type (WT),exochelin insertional biosynthesis mutant (fxbA), 
∆ESX-3 mutant, a double mutant (fxbA- ∆esx-3) and RNA refolding buffer control 
(fxbA- HMCK) in low iron Sauton’s medium. The aptamer experimental growth 
curves were performed on the fxbA-background (A) (fxbA-G31) and (B) (fxbA-
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